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ABSTRACT 
Arylsulfatase A (ARSA) is the lysosomal enzyme implicated in most cases of 
Metachromatic Leukodystrophy (MLD), a rare but severe lysosomal storage disorder 
belonging to the group of sphingolipidosis. A relatively frequent condition among the 
general population is denominated Arylsulfatase A Pseudodeficiency (ARSA-PD), and 
is characterised by a low activity of this enzyme, not associated with the MLD clinical 
phenotype. 
In this work, the genetic epidemiology of both these ARSA deficiencies have 
been studied by the molecular characterisation of Portuguese MLD patients and by the 
determination of the frequency of the ARSA-PD associated alleles in the general 
population. Among the patients characterised, we identified eight different mutations, 
four of them being novel. For mutation IVS2+1G>A, one of the most frequent null 
mutations associated with late infantile MLD, we found the highest frequency reported 
in Europe (60%). Among the general Portuguese population, approximately 18% of the 
individuals are carriers of one of the three ARSA-PD associated alleles. This is the 
highest value reported in a European population and demonstrates the importance of 
this condition in Portugal. 
Analysis of the haplotype associated with ARSA-PD alleles and with the MLD 
causal mutations was also done, in order to contribute to the elucidation of the origin, 
spreading and actual distribution of these alterations among the populations, and in this 
way also contributing to the identification of risk groups. The possible existence of 
common ancestors for several MLD causal mutations, including the null mutation 
IVS2+1G>A, is suggested by our results. In the case of the ARSA-PD associated 
alleles, only one of them has a conserved haplotype, thus suggesting a unique origin. 
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Expression studies were performed that proved the causality of three novel 
missense mutations (F219V, C300F, P425T). With the aim of contributing to the 
elucidation of the genotype-phenotype correlations in MLD, the biochemical 
characterisation of these mutations was also done. All of them were found to cause a 
reduction in ARSA activity, two of them having almost null activity (F219V, C300F). 
All the mutated enzymes were shown to be unstable, to have reduced specific activity 
and to be partially retained in the endoplasmic reticulum. Mutations P425T and C300F 
were both found to interfere with ARSA octamerization and this may be the cause of an 
increased accessibility of P425T-ARSA and C300F-ARSA to the lysosomal proteases, 
thus explaining their low stability. 
The existence of a general genotype-phenotype correlation in MLD seems to be 
corroborated by our results, in spite of the finding of some inter and intrafamilial 
heterogeneity among the adult patients. 
Although the individuals with ARSA-PD do not develop the clinical symptoms 
characteristic of MLD, the possibility of its contribution to the pathogenesis of other 
pathologies has been speculated for long. To try to contribute to the clarification of this 
question, the frequency of the ARSA-PD associated alleles was also determined in a 
group of Portuguese schizophrenic patients. Our results seem to indicate a higher 
susceptibility of ARSA-PD individuals to develop schizophrenia. 
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RESUMO 
A Leucodistrofía Metacromática (MLD) é uma doença lisossomal de sobrecarga 
rara, mas grave que se inclui no grupo das esfingolipidoses e que na maioria dos casos é 
devida à deficiência na enzima lisossomal Arilsulfatase A (ARSA). Na população em 
geral observa-se com relativa frequência uma condição denominada Pseudodeficiência 
em Arylsulfatase A (ARSA-PD), que é caracterizada por uma baixa actividade desta 
enzima, mas não está associada ao fenótipo clinico da MLD. 
Neste trabalho estudou-se a epidemiologia genética destas duas deficiências em 
ARSA através da caracterização molecular de doentes portugueses com MLD e da 
determinação da frequência dos alelos associados à ARSA-PD na população portuguesa 
em geral. O estudo dos doentes portugueses com MLD permitiu a identificação de oito 
mutações diferentes, quatro das quais identificadas neste trabalho pela primeira vez. 
Relativamente à mutação IVS2+1G>A, uma das mutações nulas mais frequentemente 
associada com a forma clinica infantil tardia da MLD foi encontrada a frequência mais 
elevada até à data descrita numa população europeia de doentes com MLD (60%). Na 
população portuguesa em geral, verificou-se ainda que aproximadamente 18% dos 
indivíduos são portadores de um dos três alelos associados à ARSA-PD. Este é o valor 
mais elevado já descrito numa população europeia e demonstra a importância desta 
condição em Portugal. 
A análise do haplótipo associado aos alelos responsáveis pela ARSA-PD e aos 
alelos causais da MLD também foi efectuada, numa tentativa de contribuir para a 
elucidação da origem, dispersão e distribuição actual destas alterações em diferentes 
populações, desta forma contribuindo também para a identificação de grupos de risco. 
Os resultados obtidos sugerem a existência de ancestrais comuns para várias mutações 
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causais da MLD, incluindo a mutação IVS2+1G>A, cuja elevada frequência em 
Portugal já foi referida. Relativamente aos alelos associados à ARSA-PD, os resultados 
obtidos sugerem uma origem única para apenas um deles, cujo haplótipo é conservado. 
Para confirmar a causalidade de três mutações missense descritas de novo 
(F219V, C300F, P425T) foram efectuados estudos de expressão. Com o objectivo de 
contribuir para a elucidação da correlação genótipo-fenótipo na MLD, foi também 
efectuada a caracterização bioquímica destas mutações. As três mutações estudadas 
causam a redução da actividade da ARSA; para duas delas (F219V, C300F) a actividade 
observada é praticamente nula. Foi também observada instabilidade, actividade 
específica reduzida e retenção parcial no retículo endoplasmático, para as três enzimas 
mutadas estudadas. Os estudos efectuados permitiram ainda observar que as mutações 
P425T e C300F interferem com a octamerização da ARSA. Esta menor capacidade de 
octamerização poderá contribuir para o aumento da acessibilidade das proteínas 
mutadas às proteases lisossomais, explicando desta forma a sua baixa estabilidade. 
Apesar de ter sido observada alguma heterogeneidade inter e intrafamiliar, 
particularmente entre os doentes adultos, os resultados obtidos neste trabalho parecem 
também corroborar a existência de uma correlação genótipo-fenótipo geral na MLD. 
Apesar dos indivíduos com ARSA-PD não desenvolverem os sintomas clínicos 
característicos da MLD, a possibilidade da contribuição desta condição para a 
patogénese de outras doenças constitui desde há muito uma hipótese que continua em 
estudo. Para tentar contribuir para a clarificação desta questão, a frequência dos alelos 
associados à ARSA-PD também foi determinada num grupo de doentes portugueses 
com esquizofrenia. Os resultados obtidos sugerem uma maior susceptibilidade dos 
indivíduos portadores da ARSA-PD para desenvolver esquizofrenia. 
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RESUME 
La Leucodystrophie Métachromatique (MLD) est une maladie lysosomale de 
surcharge rare, mais néanmoins grave qui est inclut dans le groupe des sphingolipidoses 
et qui, dans la plupart des cas, est due à une déficiente activité de 1' enzyme du 
lysosome Arylsulfatase A (ARSA). Dans la population en général, on observe, avec 
relative fréquence, une condition dénommée Pseudodéficience en Arylsulfatase A 
(ARSA-PD), qui est caractérisée par une diminuition importante de l'activité de cette 
enzyme, mais dont la diminuition d'activité n' est pas associée au phénotype clinique de 
la MLD. 
Dans ce travail, on a étudié 1'epidemiologic génétique de ces deux types de 
déficiences en ARSA à travers la caractérisation moléculaire des malades portugais 
avec MLD e la détermination de la fréquence des alleles associés à 1' ARSA-PD dans la 
population portugaise en général. L' étude des malades portugais avec MLD a permis 
l'identification de huit mutations différentes, dont quatre ont été décrites pour la 
première fois dans ce travail. En ce qui concerne la mutation IVS2+1G>A, une des 
mutations nulles plus fréquement associée à la forme clinique infantile tardive de la 
MLD, on a découvert que la fréquence de cette mutation (60%) est la plus élevée parmi 
les populations européennes de malades avec MLD. On a vérifié que dans la population 
portugaise à peux prés 18% des individus sont hétérozygotes pour un des trois alleles 
associés à l'ARSA-PD. Cette fréquence est la plus élevé des fréquences décrites dans 
les pays européens ce qui pose des problèmes particulières dans l'étude de la MLD au 
Portugal. 
L'analyse de 1' haplotype, associé aux alleles responsables de l'ARSA-PD et aux 
alleles pathologiques de la MLD, a aussi été réalisé dans le but d' élucider l'origine, la 
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dispersion et la distribution actuelle de ces altérations dans des différents populations, 
ce qui peu permettre l'identification des groupes de risque. Les résultats obtenus 
suggèrent 1' existence d' ancêtres communs pour diverses mutations pathologiques de la 
MLD, ce qui est aussi valable pour la mutation IVS2+1G>A, dont on a déjà référée la 
fréquence élevée au Portugal. Relativement aux alleles associés à l'ARSA-PD, 
seulement pour un de ces alleles, dont l'haplotype a été conservé, les résultats obtenus 
suggèrent une origine unique. 
Pour confirmer la causalité des trois nouvelles mutations missenses (F219V, 
C300F, P425T), on a réalisé des études d' expression. Dans le but de déterminer 1' 
existence d' une corrélation génotype-phénotype dans la MLD, on a aussi réalisé la 
caractérisation biochimique de ces mutations. Les trois mutations étudiées provoquent 
une réduction de l'activité de l'ARSA, et deux de ces mutations (F219V, C300F) 
originent une activité presque nulle. Différents characteristiques des trois enzymes 
mutées ont été étudiées ce qui a permit d'observer 1' instabilité, la diminuition de 1' 
activité spécifique et la rétention partielle au niveau du reticulum endoplasmique. Les 
études réalisées ont permis aussi d' observer que les mutations P425T et C300F 
interfèrent avec F octamérization de l'ARSA. Cette diminuition de leur capacité d' 
octamérization peut contribuer pour une meilleure accessibilité des protéines mutées 
aux proteases lysosomiques, ce qui explique leur faible stabilité. Malgré le fait d'une 
certaine hétérogénéité inter et intra familial, particulièrement dans les cas des malades 
adultes, les résultats obtenus dans ce travail semblent aussi corroborer l'existence d'une 
corrélation génotype-phénotype dans la MLD. 
Même si les individus ARSA-PD ne dévelloppent pas les symptômes cliniques 
caractéristiques de la MLD, la possibilité de la contribution de cette condition pour la 
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pathogenèse d'autres maladies constitue depuis longtemps une hypothèse à confirmer. 
Afin de clarifier cette question, la fréquence des alleles associés à Y ARSA-PD a aussi 
été déterminée dans un groupe de malades portugais schizophréniques. Les résultats 
obtenus suggèrent que les individus hétérozygotes pour un des alleles ARSA-PD ont 
une plus grande susceptibilité pour le dévellopment de la schizophrénie. 
8 
ABBREVIATIONS 
ARSA Arylsulfatase A 
ARSA-PD Arylsulfatase A Pseudodeficiency 
ARSB Arylsulfatase B 
BHK Baby Hamster Kidney 
BMT Bone Marrow Transplantation 
CD-MPR Cation-Dependent mannose-6-Phosphate receptor 
CGT UDP-galactose:ceramidegalactosyltransferase 
CI-MPR Cation-Independent mannose-6-Phosphate receptor 
CNS Central Nervous System 
CSF Cérebro Spinal Fluid 
CT Computed Tomography 
ER Endoplasmic Reticulum 
FGE Formylglycine-generating enzyme 
FGly Formylglycine (2-amino-3-oxopropionic acid) 
LSD Lysosomal Storage Disorders 
Man-6-P Mannose-6-Phosphate 
MSD Multiple Sulfatase Deficiency 
MLD Metachromatic Leukodystrophy 
MRI Magnetic Resonance Imaging 
PAPS 3 ' -Phosphoadenosine-5 ' -Phosphosulfate 
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PNS Peripheral Nervous System 
SAP Saposin 
SRP Signal-Recognition Particle 
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GENERAL INTRODUCTION 
General Introduction 
GENERAL INTRODUCTION 
1.1. Lvsosome and lysosomal proteins 
1.1.1. Endocytic and biosynthetic pathways to the lysosome 
Lysosomes are the major intracellular site for final degradation of a large variety 
of macromolecules that get there through the endocytic pathway, through the 
biosynthetic pathway or by fusion with phagosomes. They are part of a very complex 
endosomal network, which also includes endosomes and carrier vesicles, and whose 
importance is more and more recognised. The early endosomes are located in the 
peripheral areas of the cell and receive ligands and solutes from the extracellular space, 
through vesicles derived from the plasma membrane. Once inside the early endosomes, 
most ligands detach from their receptors due to the low endosomal pH, some are 
targeted to the lysosomes, others are recycled back to the cell surface together with the 
receptors (for review see Lloyd, 1996; Smythe, 1996). 
"Volume rich regions" of the early endosomes are transferred to the late 
endosomes. These are heterogeneous structures, with many internal membranes, that 
can be observed in the perinuclear region of the cell, and are the organelles to which the 
lysosomal enzymes are delivered (for review see Lloyd, 1996; Smythe, 1996). 
Lysosomal enzymes are delivered to the late endosome in clathrin-coated 
vesicles derived from the trans-Golgi network. These vesicles recycle back to the Golgi, 
together with the enzyme-receptors that are induced to release their cargo at low pH. 
Some lysosomal enzymes can also be delivered to the plasma membrane, from where 
they can be reinternalised by receptor-mediated endocytosis. In this case they enter the 
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General Introduction 
endocytic pathway at the early endosome level (for review see Lloyd, 1996; Smythe, 
1996). 
1.1.2. Normal pathways of biosynthesis and transport of soluble lysosomal proteins 
The pathway of lysosomal enzymes' biosynthesis involves transport through 
multiple compartments before they reach the lysosome: they are first directed to the 
endoplasmic reticulum (ER) where they are subjected to several post-translational 
modifications; they then transit through the Golgi, where they are further processed; 
they exit the Golgi via clathrin-coated vesicles and are delivered to the late endosomes. 
Upon reaching the lysosomes many of them are proteolytically processed (for review 
see Kornfeld et ai, 1989). 
The initial steps in the biosynthesis of soluble lysosomal proteins are the same as 
for secretory proteins and many membrane proteins. They have a signal sequence, 
which consists of a stretch of 15-30 mainly hydrophobic amino acids at the N-terminus, 
and that interacts with a signal-recognition particle (SRP). They are then targeted to the 
ER through the interaction of the SRP with the SRP-recognition docking protein and 
afterwards translocated into the ER's lumen, where the signal peptide is cleaved even 
before their synthesis being completed (von Figura et ai, 1986). 
Still in the ER, selected asparagine residues in the sequence Asn-X-Thr/Ser 
(where X means any amino acid except proline and asparagine) are core glycosylated 
with a pre-formed high mannose type oligosaccharide (Glc3Man9GlcNac2), donated by a 
dolichol pyrophosphate. This oligosaccharide is further processed in several reactions 
catalysed by Glucosidase I and II and alpha-mannosidase, which remove the glucose 
residues and one of the mannose residues. The first reaction specific to the synthesis of 
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soluble lysosomal enzymes is the acquisition of the Mannose-6-phosphate (Man-6-P) 
recognition marker that occurs in the Golgi, and that is catalysed by the sequential 
action of two enzymes. In a first reaction, a phosphotransferase (UDP-N-
acetylglucosamine: lysosomal enzyme N-acetylglucosamine-1-phosphotransferase) 
transfers N-acetylglucosamine 1-phosphate from UDP-N-acetylglucosamine to 
mannose residues of high mannose-type oligosaccharide side chains of lysosomal 
enzymes, originating N-acetylglucosamine-l-phospho-6-mannose residues. Then, the 
"uncovering" enzyme (N-acetylglucosamine- 1-phosphodiester alpha-N-
acetylglucosaminidase) removes the terminal N-acetylglucosamine residue, exposing 
the Man-6-P residues. Both enzymes are multisubunit proteins. The phosphotransferase 
is responsible for the specificity of the acquisition of Man-6-P markers by the lysosomal 
enzymes. This selective binding is affected by the oligosaccharide moieties of the 
lysosomal enzymes but the critical factor is the presence of particular conformation-
dependent protein domains in these enzymes. Several studies suggest that these 
recognition domains are surface patches with critical lysine residues correctly spaced 
relative to each other and to the oligosaccharide moiety (for review see Kornfeld et al, 
1989; Braulke, 1996; Kornfeld et al, 2001). 
The deficiency in the phosphotransferase is the biochemical defect of the genetic 
disorder I-Cell disease. To date no patients have been found that lack the "uncovering" 
enzyme (Kornfeld et al, 2001). 
1.1.3. Mannose-6-phosphate receptors 
The Man-6-P markers are responsible for the specific, high affinity binding of 
acid hydrolases to one of the two mannose-6-phosphate receptors, which occurs in the 
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trans-Golgi network or in the plasma membrane. These receptors mediate the targeting 
of lysosomal enzymes to lysosomes by both the biosynthetic and endocytic pathways. 
Two distinct Man-6-P receptors have been isolated and characterised, a cation-
independent mannose 6-phosphate receptor (CI-MPR) and a cation-dependent mannose 
6-phosphate receptor (CD-MPR), they are related integral membrane glycoproteins with 
apparent molecular weights of 215 KDa and 46 KDa, respectively. Both receptors have 
three structural domains: an N-terminal extracytoplasmic domain, a single 
transmembrane domain and a C-terminal cytoplasmic domain. The extracytoplasmic 
domain of the large receptor consists of 15 repeating elements, each homologous to the 
extracellular domain of the small receptor. This seems to indicate that the large receptor 
arose from multiple duplications of a single ancestral gene. In the biosynthetic pathway, 
each receptor seems to be able to functionally compensate for the loss of the other, in 
spite of the better efficiency of the CI-MPR. In the endocytic pathway, the CD-MPR 
functions very inefficiently (for review see Kornfeld et al, 1989; Braulke, 1996; 
Kornfeld etal, 2001). 
1.2. Lysosomal Storage Disorders 
The deficient catabolic activity of lysosomal hydrolases or the deficiency of 
lysosomal transporter proteins, results in the blockade of the lysosomal digestive 
process with the subsequent accumulation, within the lysosome, of undigested 
substrates that can be observed as abnormal intracellular inclusions characteristic of 
lysosomal storage disorders (LSD), (Suzuki et al, 2002). 
More than forty distinct genetic lysosomal disorders have been identified and the 
enzyme deficiency underlying the majority of these disorders has been elucidated. 
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Clinically, they consist of an heterogeneous group and usually they are classified into 
different subgroups, according to the nature of the undigested accumulated substrates. 
Although this classification is to some extent arbitrary, two major groups are 
sphingolipidoses and mucoplysaccharidoses, which are respectively characterised by the 
accumulation of sphingolipids and glycosaminoglycans due to their defective 
degradation. Glycoprotein storage disorders constitute a third group of LSD in which 
the degradation of carbohydrate chains of glycoproteins are affected resulting in the 
accumulation of oligosaccharides and glycoproteins. Neuronal ceroid lipofuscinosis 
refers to another clinically heterogeneous group of LSD characterised by the 
accumulation of ceroid lipofuscin inclusions. Apart from these groups there are still a 
miscellaneous of LSD characterised by the accumulation of several distinct substrates 
(for review see Suzuki et al, 2002). 
1.3. Metachromatic Leukodystrophy 
13.1. General definition and incidence 
Metachromatic Leukodystrophy (MLD) is a lysosomal storage disorder 
belonging to the group of sphingolipidoses. It is inherited as an autosomal recessive 
trait, and is characterised by the intrafysosomal accumulation of sulfatide (galactosyl-3-
sulfate ceramide) in different tissues and by its elevated excretion in urine, due to the 
deficient activity of the lysosomal enzyme Arylsulfatase A (E.C.3.1.6.8, ARSA) or to 
the activator protein Saposin B (SAP B) deficiency (for review see von Figura et al, 
2001). Figure 1 depicts the catabolism of sphingolipids with the indication of the 
enzymes involved and the related lysosomal disorders. The step blocked by ARSA 
activity deficiency is emphasized. 
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Figure 1 - Catabolism of major sphingolipids: enzymes involved and enzyme related 
diseases. Abbreviations: Cer - ceramide; Gal - galactose; GalCer - galactosylceramide; 
GalNAc - N-acetylgalactosamine; Glc - glucose; GlcCer - glucosylceramide; NeuAc - N-
acetylneuramic acid (sialic acid), (Suzuki et al, 2002). 
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The overall incidence of MLD is not accurately determined. Several studies, in 
different populations, indicate an incidence between 1:40000 and 1:170000 for the late 
infantile MLD due to ARSA deficiency (Gustavson et al, 1971; Guibaud et al, 1973; 
Farrell et al, 1981; Heim et al, 1997). In Australia the prevalence of MLD was 
determined to be 1: 92000 (Meikle et al, 1999). Higher incidences of MLD have been 
reported for several isolated ethnic groups: 1:75 in the Habbanite Jews living in Israel 
(Zlotogora et al, 1980), 1:8000 in the Christian Arabs living in Israel (Heinisch et al, 
1995), 1:2500 in the Eskimos and 1:6400 in the Navajo Indians (Pastor-Soler et al, 
1994; Pastor-Soler et al, 1995). Regarding MLD due to Sap B deficiency, only nine 
cases have been described up to now (Sandhoff et al, 2001). 
1.3.2. Clinical forms and pathophysiology 
According to the age of onset, there are three distinct MLD clinical forms 
associated with the deficiency of ARSA activity: a late infantile, a juvenile and an adult 
form. Late infantile patients usually show normal development during their first year of 
live, the first symptoms occurring before the 4th year. Progressively, these patients start 
to loose the ability to walk, stand and later even to sit. After the motor disturbances, 
impairment of language and mental function also develops. In the later stage of the 
disease, the child reaches an unresponsive vegetative state, and dies usually within 2 to 
4 years after onset of symptoms. The clinical features of the juvenile form of MLD 
resemble those of the late infantile form, but the age of onset varies from 4 to the late 
teens. Emotional and behavioural disturbances are frequently observed. The progression 
of the illness is slower and it may extend over a decade. The adult form of MLD has 
been reported at various ages beyond puberty, and patients can present in a very 
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different way. The initial manifestations may be signs of emotional lability, delusions, 
psychotic behaviour and dementia. Motor disturbances may only be observed in the 
final stages of the disease, which may follow several decades after the onset of the 
emotional and mental disturbances (for review see Graljaard, 1980). 
Several complementary examinations can be important for the clinical diagnosis 
of MLD. Brain Computed Tomography (CT), Magnetic Resonance Imaging (MRI), 
measurements of nerve conduction velocity and evoked potential studies are of the 
major importance. An abnormal low density of the cerebral white matter can be 
observed at very early stages of the disease and neurophysiological studies reveal 
decreased motor nerve conduction velocity and diminished amplitude of sensory nerve 
action potentials, indicating the presence of peripheral neuropathy. The brainstem 
auditory evoked responses and the visual evoked responses can also be abnormal. Late 
infantile patients have increased urinary sulfatide excretion and increased CSF protein 
and sulfatide content. Juvenile and adult patients usually also have elevated urinary 
sulfatide excretion, but CSF protein can present normal values. Normal CSF sulfatide 
have also been observed even in late stages of juvenile and adult MLD. The 
examination of the gallbladder can also be important because alterations can be 
observed even before the occurrence of the first neurological symptoms (for review see 
von Figura et al., 2001). 
The morphologic changes characteristic of MLD are demyelination and deposits 
of metachromatic granules in the central and peripheral nervous system and in the 
visceral organs. These granules have a diameter of 15 to 20 um, and are composed 
mainly of sulfatide (39%), cholesterol and phosphatides (Suzuki et al, 1967). 
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In the central nervous system (CNS) metachromatic granules are visible within 
macrophages, oligodendrocytes and certain groups of neurons (Takashima et al, 1981). 
The amount of CNS myelin is reduced and its "cavitation or spongy degeneration" can 
be observed. A diminished number of oligodendrocytes and a reactive gliosis in the 
demyelinated areas are also observed (von Figura et al, 2001). 
In the peripheral nervous system (PNS), the metachromatic granules are present 
in Schwann cells and in endoneurial macrophages (Martin et al, 1982). There is a 
reduced myelin sheath thickness for all fibers, but the ones with the greater axon 
diameter are the most affected (Alves et al, 1986; Bardosi et al, 1987). 
The progressive intralysosomal accumulation of sulfatide is not uniform in all 
tissues and organs and can lead to a loss of function or contribute to the fatal outcome of 
the disease, depending on the tissue. Several organs accumulate sulfatide: the kidneys 
(LeRoy et al, 1973; Eto et al, 1982), gallbladder (Tesluk et al, 1989; Malde et al, 
1997), liver parenchymal cells and epithelial cells of the intrahepatic bile ducts 
(Resibois et al, 1971), islets of Langerhans (Hagberg et al, 1962), anterior pituitary 
(Wolfe et al, 1964), adrenal cortex (Wolfe et al, 1964) and the sweat glands (Goebel et 
al, 1989). In adult patients, metachromatic material accumulation was also reported in 
the testes, this is probably not sulfatide but seminolipid. Lactosylsulfatide levels are also 
increased, especially in the kidney (Scott et al, 1993). 
Besides the increase in the amount of sulfatides, a marked decrease in the level 
of other myelin lipids like galactocerebroside, cholesterol and sphingomyelin can also 
be observed (Norton et al, 1982; Stallberg-Stenhagen et al, 1965). The 
galactocerebroside:sulfatide ratio can be decreased from 3 (approximate value for 
normal white matter) to 1 (Svennerholm et al, 1963; Harzer et al, 1987) and the 
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amount of lysosulfatide, the deacylated form of sulfatide, can be increased 50-100 times 
(Toda et al, 1989; Toda et al, 1990). 
The demyelination occurring in MLD seems to be secondary to the sulfatide 
induced metabolic failure of the Schwann cells (PNS) and oligodendrocytes (CNS), and 
at least three different mechanisms have been suggested to explain the myelin 
breakdown that is observed in MLD patients. It can result from the defective resorption 
of sulfatides in the innermost part of the myelin sheath, it can be due to an altered 
structure leading to its instability or it can result from the accumulation of lysosulfatide, 
a highly cytotoxic compound whose accumulation is described in different tissues of 
MLD patients. The demyelination of long tracts can explain the decreased nerve 
conduction velocity, the decreased synaptic transmission and the increase in the latency 
period of evoked potentials that are observed in MLD patients. The intellectual 
impairment can result from the damage of the neurons and from a scrambling of 
information due to the slow nerve conduction velocity (for review see von Figura et al, 
2001). 
t.4. Structural similarities of sulfatases and biochemical diagnosis of the sulfatases' 
deficiencies 
1.4.1. The sulfatases' family 
Thirteen different sulfatases participate in the hydrolysis of complex sulfate ester 
substrates in the vertebrates (Parenti et al, 1997). Eight of these sulfatases are involved 
in the removal of sulfate from glycosaminoglycans, glycopeptides and glycolipids, and 
active in the lysosome. The other ones participate in the hydrolysis of 
are 
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hydroxysteroids and are found in microsomes, endoplasmic reticulum and Golgi 
network (for review see Hopwood et al, 2001). 
The identification of at least eight human genetic diseases caused by the 
deficiency of individual sulfatase activities revealed the crucial importance of each of 
these enzymes in the catabolism of specific sulfated substrates. The deficiency in the 
lysosomal sulfatases that act on glycosaminoglycans originates five different types of 
mucopolysaccharidoses (Neufeld et al, 2001) whereas the deficiency in arylsulfatase A, 
the lysosomal sulfatase involved in the hydrolysis of a glycolipid originates the 
glycosphingolipidosis MLD (von Figura et al, 2001). X-linked ichthyosis and 
chondrodysplasia punctata are caused by deficiencies in the non-lysosomal sulfatases 
arylsulfatase C and arylsulfatase E, respectively (Franco et al., 1995; Ballabio et ai, 
2001). There is also a rare disorder, Multiple Sulfatase Deficiency (MSD), in which the 
activity of all sulfatases is deficient and the patients have clinical features characteristic 
of MLD, mucopolysaccharidosis, X-linked ichthyosis and chondrodysplasia punctata. 
This was the first indication that sulfatases have a common structural feature essential 
for their catalytic activity (Hopwood et al, 2001). 
The members of this sulfatases' family are highly conserved from bacteria to 
man, with a very high degree of homology between their amino acid sequence (Franco 
et al, 1995; Parenti et al, 1997; Knaust et al, 1998; von Figura et al, 1998) and their 
three-dimensional structure (Bond et al, 1997; Lukatela et al, 1998; Waldow et al, 
1999). The N-terminal third of these proteins presents the highest homology, including 
a cysteine that is converted to a Ca-formylglycine amino acid derivative (FGly), and 
that was found in sulfatases of prokaryotic (Dierks et al, 1998; Miech et al, 1998), 
lower eukaryotic (Selmer et al, 1996) and human origin (Schmidt et al, 1995). This 
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FGly residue (2-amino-3-oxopropionic acid) results, in all eukaryotic sulfatases, from 
the oxidation of a cysteine residue (Schmidt et al, 1995), and probably occurs at a late 
cotranslational or early posttranslational step of protein tanslocation (Dierks et al, 
1997; Fey et al, 2001). The finding that this posttranslational modification is required 
for the activity of all sulfatases and that it is defective in the patients with MSD, 
suggested that the molecular basis of this disease resides in a gene or genes codifying 
the cysteine to formylglycine conversion machinery (Schmidt et al, 1995). Although it 
was known for some time that the FGly-modifying machinery consists of soluble 
components of the ER (Fey et al, 2001), only very recently the formylglycine-
generating enzyme (FGE) was identified (Cosma et al, 2003; Dierks et al, 2003). FGE 
is codified by a nine exons gene (SUMF1) that spans approximately 106 Kb in 
chromosome 3p26. The cDNA encoding human FGE predicts a protein with 374 amino 
acids and a single Asn glycosylation site. FGE resides in the endoplasmic reticulum and 
seems to be both essential and limiting for the synthesis of catalytically active 
sulfatases. Another protein, codified by a gene designated SUMF2, was also identified 
as having some capacity to activate sulfatases, but is significantly less active than 
SUMF1 and its importance in MSD remains to be elucidated (Cosma et al, 2003; 
Dierks et al, 2003). 
1.4.2. Biochemical diagnosis of MLD 
In spite of its high specificity for their natural substrates "in vivo", some 
sulfatases cleave a wide range of synthetic substrates "in vitro", which can raise some 
difficulties in the biochemical diagnosis of some sulfatases enzymatic deficiencies. 
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The biochemical diagnosis of MLD is usually done by ARSA activity 
determination in peripheral blood leukocytes or fibroblasts, using artificial substrates as 
the p-nitrocatechol sulfate or 4-methylumbelliferyl sulfate. However, these substrates 
are also degraded by other sulfatases and thus require the use of assay conditions that 
selectively diminish their interference, specially the one from the co-localizing 
lysosomal sulfatase Arylsulfatase B (ARSB). Different assays have been developed for 
determination of ARSA activity based on the inhibition of ARSA and ARSB by Ag+ 
and high concentrations of NaCl, respectively (Baum et al, 1959; Christomanou et al, 
1977). The differential tolerance of arylsulfatases toward low temperatures can also be 
used to efficiently distinguish ARSA and ARSB activities (Lee-Vaupel et al, 1987). 
Another possibility to increase the specificity of the assays is the physical 
separation of the different arylsulfatases that can be accomplished by ion exchange 
chromatography (Humbel, 1976) or electrophoretic techniques (Chang et al, 1984; 
Alves et al, 1986; Li et al, 1992). The use of radioactively labelled sulfatide, the 
natural substrate of ARSA, allows the specific determination of its activity, but it is a 
very expensive, time consuming and technically difficult method (Leinekugel et al, 
1992). 
Besides the existing problems in the determination of ARSA activity, two 
different conditions cause important problems in the biochemical diagnosis of MLD: the 
Arylsulfatase A pseudodeficiency (ARSA-PD), a condition not associated with the 
clinical symptoms of MLD and that will be discussed later in this chapter, and MLD 
due to Saposin B deficiency. In the case of ARSA-PD, low ARSA activity levels are 
measured "in vitro" using artificial substrates, in the case of MLD due to Saposin B 
deficiency, normal ARSA levels are determined with artificial substrates. In both cases 
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MLD can be excluded or proved by a sulfatide-loading assay in cultured fibroblasts 
(Kihara et al, 1980; Fluharty et al, 1978) and by a urine sulfatide determination 
(Molzer etal, 1992). 
1.5. Natural substrates of ARSA 
1.5.1. Biological importance of sulfatide and other natural substrates of ARSA 
Sulfatides (galactosylceramide 3-sulfate) are the main sphingosine-containing 
sulfated glycolipids whose lysosomal accumulation is characteristic of MLD. They 
occur in higher amounts in central and peripheral nervous system and in the kidney but 
can also be observed in other tissues, particularly those with a rich excretory epithelium 
(Krivan et al, 1989; Natomi et al, 1990; Takamatsu et al, 1992), and in body fluids 
(Zhu et al, 1991; Molzer et al, 1992). The fatty acid pattern of sulfatides is dependent 
on the developmental stage and on the tissue. The fact that in MLD each tissue 
accumulates the corresponding normal fatty acid pattern of structurally normal 
sulfatides supports the idea of an independent accumulation in each tissue 
(Svennerholm et al, 1962; Malone et al, 1966). 
Sulfatides are localized on the extracellular surface of the myelin sheath (Norton 
et al, 1973; Arvanitis et al, 1992) and are responsible for the preservation of the 
insulator function of myelin (Bosio et al, 1996; Coetzee et al, 1996). 
To determine the importance of the main glycolipids in myelin 
(galactocerebroside and sulfatide), a mouse model was generated that lack both 
glycolipids (UDP-galactose:ceramide galactosyltransferase (CGT) deficient mice), 
(Coetzee et al, 1996). These mice do not have a dramatic inhibition of myelination, as 
it could be expected, but they present an abnormal central nervous system myelin with 
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ultrastructural alterations that seem to reflect abnormal axo-glia adhesion/ recognition 
mechanisms (Marcus et al, 2002a) and they develop progressive neuropathological 
symptoms leading to early death (Coetzee et al, 1996). The myelin glycolipids and the 
myelin-associated glycoproteins seem to act together to promote myelin axo-glial 
adhesion and structural maintenance of the paranode (Marcus et al, 2002a; Marcus et 
al, 2002b). A mouse model lacking cerebroside sulfotransferase activity was also 
recently generated (Honke et al, 2002). These mice, which lack sulfatide in brain and 
seminolipid in testis, develop neuropathological symptoms and, in spite of the 
preservation of compact myelin, they have abnormalities in paranodal junctions. 
Sulfoglycolipids thus seem to have an important role in myelin function and 
spermatogenesis (Honke et al, 2002). 
Sulfatides also seem to be important for several other biologic processes like, for 
example, the active sodium transport (as a cofactor for Na+/ K+-ATPase), the binding of 
opiates, GABA and serotonin to their receptors, the modulation of the activity of 
enzymes such as phospholipase A2, calmodulin-dependent cyclic nucleotide 
phosphodiesterase and phosphatidylinositol phosphate 3-kinase, the specific binding of 
several cellular adhesion molecules or the activation of several clotting substances (see 
von Figura et al, 2001 for review). Sulfatides are expressed in the platelet surface and 
seem to have a role in platelet adhesion and aggregation by modulation of platelet 
activation (Merten et al, 2001; Devaiah et al, 2000). It is also known that sulfatides 
bind L-selectin, a lymphocyte-homing receptor (Suzuki et al, 1993) that seems to 
modulate lymphocyte activation during cell adhesion and transmigration (Ding et al, 
2003), and several infectious organisms also have specific domains for sulfatide binding 
(Brennan et al, 1991; Cerami et al, 1992; Muller et al, 1993; Olson et al, 1993). 
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Sulfatides seem also to be involved in controlling insulin secretion, in stabilising 
insulin hexamer crystals and in mediating the conversion of insulin hexamers to the 
biological active monomers (Buschard et ai, 2002; Osterbye et al, 2001). It has also 
been shown that insulin induces cerebroside sulfotransferase in oligodendrocyte's cell 
cultures (Ferret-Sena et ai, 1990). The physiological significance of sulfatides' function 
in all these mechanisms is still unknown. 
The other three sulfated glycolipids represented in Figure 2 are less important in 
MLD. 
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Figure 2 - Sulfated glycolipids important for MLD. In spite of the recent identification of 
other sulfated glycolipids in different tissues, only sulfatides, lactosylceramide 3-sulfate and 
seminolipid have been shown to be desulfated by ARSA in humans. Sulfatides are most 
important in central and peripheral nervous system, but they are also abundant in the kidney. 
Lactosylceramide 3-sulfate is also found in human kidney and urine, but it is not present in the 
brain. Seminolipid is the major sulfolipid in mammalian testes and sperm and it also could not 
be found in brain. Lysosulfatide is a highly cytotoxic compound that has been reported to 
accumulate in MLD, however the enzymatic deacylation of sulfatide to lysosulfatide was never 
proven (modified from von Figura et al, 2001). 
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Lactosylceramide 3-sulphate can also be found in the kidney (Martensson et al, 1966), 
lysosulfatide occurs in small amounts in the cerebral white matter, spinal cord and 
kidney (Toda et al, 1990) and seminolipid is the major glycolipid constituent of mature 
mammalian testes and sperm (Kornblatt et al, 1974). Sandhoff et al (2002) have shown 
that a more complex sulfatide, gangliotetraosylceramide 3, 3-bis-sulfate also 
accumulates in the ARSA-deficient mice kidney, together with galactosylceramide 3-
sulphate and lactosylceramide 3-sulphate. The authors thus suggested that in the murine 
kidney, ARSA is probably the only sphingolipid-sulfatase cleaving the galactosyl-3-
sulfate bond. The analysis of the lipids accumulating in the kidney of mice models for 
several glycosphingolipid disorders also allowed the authors to suggest that the human 
pathway for complex sulfatides is very similar to that of mice. 
1.5.2. Biosynthesis and degradation of sulfatide 
Sulfatides result from the sulfation of galactosylceramide by reaction with 3'-
phosphoadenosine-5'-phosphosulfate (PAPS), in a reaction catalysed by a microsomal 
sulfotransferase (Farrell et al, 1971). They account for 3.5-4% of the total lipids of 
myelin (Norton et al, 1982). Its synthesis is maximal at the myelination period and can 
occur in neurons, oligodendroglial cells, cells of glial origin and cells from the renal 
tubule epithelium (Benjamins et al, 191 A; Ishizuka et al, 1978). 
The degradation of 3-sulfogalactosyl-containing glycolipids begins with its 
desulfation by the lysosomal enzyme ARSA, in a reaction dependent on Saposin B 
(Mehl et al, 1965; Shapiro et al, 1979). The proposed mechanism for this reaction is 
referred in the next section of this chapter. 
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1.6. Proteins involved in sulfatide hvdrolvsis: Arvlsulfatase A 
1.6.1. Arvlsulfatase A gene 
The ARSA gene has been mapped to the chromosome 22ql3 (Bruns et al, 1978; 
Phelan et al, 1992). A genomic clone containing the entire human ARSA gene was 
isolated and characterised in 1990 (Kreysing et al, 1990). The ARSA gene consists of 
eight exons distributed along 3,2 Kb (GeneBank sequence X52150). Its promotor has no 
typical TATA or CAAT box sequences, but four major transcription initiation sites were 
identified between positions -367bp and -387bp, upstream of the start codon. As it is 
characteristic of housekeeping gene promoters, besides the lack of the TATA box, the 
ARSA promoter has a high GC content, with several GC boxes in typical positions for 
interaction with the transcription factor Spl, and a CpG island (Kreysing et al, 1990). 
1.6.2. Arylsulfatase A mRNA 
The ARSA cDNA hybridises to three different mRNA species (2.1 Kb, 3.7 Kb 
and 4.8 Kb) that differ in their 3' untranslated sequences, probably due to the use of 
different polyadenylation signals. The primary transcript is cleaved and polyadenylated 
95 nucleotides after the termination codon, originating the 2.1 Kb mRNA. This 
transcript accounts for 90% of ARSA polyadelylated mRNA. The low ARSA activity 
resulting from a polymorphism destroying this polyadenylation signal suggests that the 
translational efficiency of the other transcripts is very low (Gieselmann et al, 1989). 
1.6.3. Arylsulfatase A protein 
A full-length cDNA for human ARSA was cloned and sequenced in 1989 (Stein 
et al, 1989). It has an open reading frame of 1521 nucleotides that codes for 507 amino 
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acids, from which the first 18 constitute a typical sequence for translocation into the ER. 
The authors reported that the ARSA does not seem to be subjected to any process of 
maturation by proteolytic processing in the lysosome. 
The predicted ARSA sequence contains three potential N-glycosylation sites 
(Asnl58, Asnl84, Asn350). All three sites can be used and the oligosaccharides seem to 
be phosphorylated independently of their position. However the Asnl84 seems to be 
less efficiently phosphorylated. The first and second sites, both encoded in exon 3, seem 
to be mutually exclusive and glycosylation in one of these sites and in site three (exon 
6), seems to be sufficient for correct sorting of ARSA (Gieselmann et al, 1992). 
In human fibroblasts, ARSA is synthesised as a precursor with a mean apparent 
molecular mass of 62 KDa, which is slowly converted in the lysosome to a 60.5 KDa 
form. This conversion is thought to be due to oligosaccharides' trimming and the 60.5 
KDa form is thought to represent the mature form. Just about 90% of the ARSA forms 
seem to contain two side chains of the high-mannose or hybrid type oligosaccharides; 
the other 10% contain probably one complex and one high-mannose oligosaccharide 
(Waheed et al, 1982). Heterogeneity for carbohydrate composition in different tissues 
can be observed as was also reported for other lysosomal enzymes (Hasilik et al, 1982). 
1.6.4. Arylsulfatase A three dimensional structure 
The three dimensional structure of human ARSA, based on X-ray diffraction 
data to 2.1 Â resolution, was reported by Lukatela et al (1998). In acidic milieu, 
characteristic for lysosomes, ARSA exists as an octamer that at neutral pH dissociates 
into dimers. The ARSA monomer has a globular hat-like structure. Two monomers 
associate through contacts involving one (3-strand and four loops localised on the "flat" 
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part of the hat-like structure. These contacts are made through direct hydrogen bonds 
and water-mediated hydrogen bonds, which originate a very strong monomer-monomer 
interaction. In the homodimer, which presents an almost cylindrical form, the two 
monomers are related by a crystallographic 2-fold axis (Lukatela et al, 1998). 
The octamers, observed at acidic pH, are composed of dimers (a2)4 and seem to 
be stabilised by hydrophobic interactions. The pH dependent dimer-octamer association 
is due to protonation of Glu424. The amino acid residues Cis-Pro425, Pro426, Phe398, 
Phe399 and Ala422, form an hydrophobic cavity that encloses Glu424 and several water 
molecules. At acidic pH, the Glu424 residue is protonated and establishes an 
intermolecular hydrogen bond with the oxygen of Phe398, thus stabilizing the octamer. 
At neutral pH, this hydrogen bond is no longer possible, and thus the octamer is 
destabilized by electrostatic repulsion between the negatively charged Glu424 side 
chains (Lukatela et al, 1998). 
The secondary structure of the enzyme is of the a/p type (see Figure 3) and the 
enzyme consists of two domains. One domain includes the N-terminal region and 
contains a large central beta-sheet, flanked by alpha-helices. The other domain, which 
includes the C-terminal region, is smaller and consists of a small antiparallel beta-sheet 
tightly associated with a long C-terminal alpha-helix. The two beta-pleated sheets are 
connected by indirect hydrogen bonds through several buried water molecules and 
covalently linked by disulfide Cys300-Cys414 (Lukatela et al, 1998). 
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Figure 3 ­ Secondary structure of ARSA. Alpha­helices are indicated in blue and beta­strands 
are indicated in grey. Putative amino acid residues in the active site and glycosylation sites are 
indicated in green and red, respectively (adapted from Waheed et al, 1982; Lukatela et al, 1998 
and Waldow et al, 1999). 
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1.6.5. Arylsulfatase A active site 
The catalytic site of ARSA includes the conserved FGly residue, critical for 
sulfatases activity, at position 69, where the cDNA sequence predicts a cysteine 
(Lukatela et al, 1998). The sequence information essential for the cysteine conversion 
in sulfatases is contained in a stretch of amino acid residues from positions -1 to +11 
regarding the cysteine to be modified. In ARSA, two sequence motifs were identified 
within this region: a CTPSR motif, starting with Cysteine 69, and a second auxiliary 
AALLTGR motif, including residues from position 74 to 80. Apart of the modified 
cysteine, and in spite of its high conservation, no other residue seems to be strictly 
essential. However, systematic substitution of the amino acid residues in the CTPSR 
motif demonstrated that the cysteine, proline and arginine are key residues. The serine 
and threonine can be individually, but not simultaneously substituted without interfering 
in the cysteine oxidation (Dierks et al, 1999). The importance of the auxiliary motif 
seems to be related with its secondary structure (Schmidt et al, 1995; Dierks et al, 
1999). 
The FGly residue, that is essential for the enzyme catalytic activity, is localised 
in the bottom of a positively charged cavity that constitutes the active binding site for 
the negatively charged sulfate group of the substrate. This residue is involved in the 
coordination of an Mg2+ metal ion, together with amino acid residues Asp29, Asp30, 
Asp281 and Asn282. All these residues are conserved among sulfatases, except for 
Asn282 that can be replaced by Gin or His, residues that also have metal coordination 
capacity. All these residues are important for the general structure of the active site 
(Waldow et al, 1999). Lys302, His229, Serl50, Arg73, Hisl25 and Lysl23 are the 
other putative active site residues, and they are thought to be involved in the ARSA 
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catalytic mechanism. AU the residues involved in sulfate binding or in catalysis have the 
capacity to establish hydrogen bonds, originating a net that constitute the ARSA 
functional catalytic system (Waldow et al., 1999). 
1.6.6. Arylsulfatase A reaction mechanism 
Based on the ARSA crystal structure and on its high degree of structural 
similarity with the E. colt alkaline phosphatase, Lukatela et al. (1998) proposed a 
catalytic mechanism for ARSA that includes a nucleophilic attack on the sulfate sulfur 
atom, by one of the hydroxyls of the FGly, and a formation of a covalent intermediate. 
The functions of nine conserved putative active site amino acid residues in ARSA 
(Asp29, Asp30, Asp281, Asn282, Hisl25, His229, Lysl23, Lys302 and Serl50) were 
analysed by Waldow et al. (1999), in a study in which each of these residues was 
conservatively substituted and the Km, Vmax and pH optimum of the mutants toward 
the artificial substrate p- nitrocatechol sulfate determined. According to the authors each 
of these residues has a critical function for ARSA catalytic activity. However, the fact 
that ARSA degrades its substrate very fast makes it difficult to characterise the 
intermediate complexes. More recently, von Bulow et al. (2001) reported the crystal 
structure of two ARSA mutants, Cys69Ala and Cys69Ser-ARSA, in complex with p-
nitrocatechol sulfate. For the first mutant there is no possibility of formation of the 
covalent substrate-enzyme intermediate, in spite of the preservation of the geometry and 
polarity of the active site environment. For the second mutant the catalysis can occur, 
but the release of the sulfate from the enzyme is blocked, which allows the 
characterisation of the sulfate intermediate. According to the authors, the sulfate group 
binds the enzyme through hydrogen bonds with the positively charged side chains of 
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His229 and Lys302. Weaker bonds are also established with the side chains of Lysl23 
and Serl50, and to the main chain nitrogen of residue Cys69 and Mg . The sugar 
residue of the sulfatide, the ARSA natural substrate, could eventually substitute the 
hydroxyl groups of p-nitrocatechol sulfate in the interaction with the charged side 
chains of Arg288 and Aspl52. The side chains of His405, Glul55 and Aspl73 are also 
probably involved in interactions between the enzyme and the sulfatide sugar residue. 
The amino acid residues Leu68, Val91 and Val93 can yet stabilize the positioning of the 
sulfatide hydrophobic chains through hydrophobic interactions (von Bûlow et al, 
2001). 
The proposed mechanism for sulfatide degradation by ARSA is depicted in 
Figure 4. In the resting form of ARSA, the FGly group is probably hydrated and acting 
as a geminai diol. One oxygen, from one of the hydroxyls, can start a nucleophilic 
attack on the sulfur atom initiating the hydrolysis via a transesterification step, and thus 
originating a covalent intermediate. The second hydroxyl can eliminate the sulfate 
through a C-O cleavage and regenerate the aldehyde, whose hydration completes the 
catalytic cycle (Lukatela et al., 1998; von Biilow et al, 2001). 
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Figure 4 - Proposed mechanism for the hydrolysis of sulfatide by ARSA. The FGly group 
acts like a geminai diol. The sulfur atom suffers a nucleophilic attack from one of the hydroxyls 
and an enzyme-sulfate ester intermediate forms, while a residual alcohol is released. The sulfate 
is then eliminated by an intramolecular rearrangement that cleaves the ester bond and 
regenerates the aldehyde. The hydration of the aldehyde completes the catalytic cycle (modified 
from Waldow et al, 1999). 
1.7. Proteins involved in sulfatide hydrolysis: Saposin B 
The small protein Saposin B results from the proteolytic processing of 
prosaposin, a 524 amino acid protein, which is composed of four homologous domains. 
Each of these domains generates, by lysosomal proteolytic processing, a mature 
independent glycoprotein: SAP-A, SAP-B, SAP-C and SAP-D. The SAP precursor gene 
covers a region of 17Kb in chromosome 10q21-23 (for review see Sandhoff et al, 
2001). 
Saposin B acts by extracting specific lipids from membranes and forming 
soluble activator-lipid complexes that are recognized by ARSA. There is no interaction 
between the activator and the enzyme (Sandhoff et al, 2001). The crystal structure of 
human Saposin B was recently reported and revealed an unusual shell like structure 
dimer that can be important to do the extraction of target lipids from membranes (Ann 
et al, 2003a). Stability studies revealed that it is extremely resistant to pH, heat and 
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proteases, which can be related with three intrachain disulfide bridges that are part of its 
structure (Ahn et al, 2003b). 
1.8. Arylsulfatase A pseudodeficiency 
1.8.1. Definition of Arylsulfatase A-pseudodeficiency 
Arylsulfatase A-pseudodeficiency (ARSA-PD) is a relatively frequent condition 
among the general population (1-2%), which is characterised by a reduction to 5-15% of 
ARSA activity against artificial substrates. However, the "in vivo" activity of this 
altered ARSA is sufficient to prevent the accumulation of sulfatide and the development 
of a MLD phenotype (reviewed in von Figura et al, 2001). 
1.8.2. Molecular lesions in the origin of ARSA-PD 
Gieselmann et al (1989) identified the molecular defects in the origin of ARSA-
PD, they consist of two A—»G transitions in the ARSA coding gene (nucleotides 2417 
and 3352, according to the GeneBank sequence X52150), which can be found isolated 
or in combination with each other. The first mutation changes asparagine 350 into 
serine and causes the abolition of one ARSA glycosylation site, which explains the 
smaller size of ARSA in pseudodeficiency (2-4 KDa less). The second mutation 
destroys the first polyadenylation site downstream of the stop codon, leading to the loss 
of the 2.1 Kb mRNA species that normally represents 90% of the ARSA polyadenylated 
mRNA. The composed allele, with both alterations, is usually known as the ARSA-PD 
allele. In this work, and in spite of the existing controversy regarding the amount of 
ARSA activity associated with the two alleles with only one of the ARSA-PD 
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associated alterations, we also refer to these alleles as low ARSA activity alleles or 
ARSA-PD associated alleles. 
1.8.3. Biochemical characterisation of the ARSA-PD protein 
According to Gieselmann et al (1989) the loss of the major ARSA mRNA 
species, due to the destruction of the polyadenylation site, can by it self explain the 90% 
reduction in the synthesis of ARSA, which results in the low ARSA activity associated 
with the complex ARSA-PD allele in human fibroblasts. This observation is not 
confirmed by Harvey et al (1998) that reported a reduction of only 69% in the ARSA 
mRNA due to the polyadenylation defect. 
There were also some contradictory observations regarding the kinetic properties 
of the ARSA-PD protein. Qu et al. (1997/ 1998), performed kinetic studies to compare 
the hydrolysis of p-nitrocatechol sulfate by ARSA, partially purified from normal 
fibroblasts or from fibroblasts of a homozygote for the ARSA-PD allele. They reported 
for the ARSA-PD protein a decreased affinity for the substrate and an increased heat 
inactivation. On the contrary, Chang and Davidson (1983) and Herz and Bach (1984) 
had compared the properties of ARSA from normal fibroblasts and from MLD/ PD 
fibroblasts, and they observed identical kinetic properties, substrate affinity, optimal pH 
for activity, and sensitivity to heat denaturation and proteolytic degradation, for the 
hydrolysis of 4-methylumbelliferyl sulfate and p-nitrocatechol sulfate, respectively. 
The biochemical characteristics of the N350S-ARSA protein have also been the 
subject of contradictory reports. Its rate of synthesis was found to be normal in BHK 
transfected cells expressing the N350S-ARSA protein (Gieselmann et al, 1989) and in 
human fibroblasts of N350S homozygotes (Park et al, 1996). Its specific activity for 
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artificial substrates was also found to be normal by Gieselmann et al. (1989), Ameen et 
al. (1990) and Park et al. (1996). Only Harvey et al. (1998) reported a contribution of 
this alteration to the reduced activity of the ARSA protein, when expressed in CHO 
transfected cells. According to these authors there is also a deficient intracellular 
localization of N350S-ARSA, with 55% of the enzyme localizing to non-lysosomal 
fractions in a density gradient. On the contrary, Ameen et al. (1990) and Park et al. 
(1996) reported a normal intra-lysosomal localization for N350S-ARSA. Gieselmann et 
al. (1989) also reported a normal stability for this protein expressed in BHK transfected 
cells. However, Ameen et al. (1990) and Park et al. (1996) reported a decreased stability 
of this enzyme in human fibroblasts. 
The measure of ARSA activity using artificial substrates, in N350S 
homozygotes or hétérozygotes, also resulted in contradictory observations. Barth et al. 
(1994) and Leistner et al. (1995) reported that the N350S alteration is not responsible 
for a major reduction in ARSA activity in human leukocytes. On the contrary, Shen et 
al. (1993) and Park et al. (1996) observed a reduction in the N350S-ARSA activity in 
human fibroblasts. 
1.8.4. Clinical implications of ARSA-PD 
The relatively high frequency of ARSA-PD in the general population could be 
explained by an hétérozygote advantage, but to date there are no plausible possibilities 
for this advantage. On the other hand, many studies have been done trying to elucidate 
the existence of clinical implications for ARSA-PD, namely its contribution to an 
increased susceptibility to the development of psychiatric or neurological symptoms. 
Nevertheless, most of these studies were based on the biochemical determination of 
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ARSA activity "in vitro" or included a small number of subjects and lead to 
inconclusive results (for review see von Figura et al, 2001). 
Conzelmann and Sandhoff (1984) proposed a theoretical model to explain the 
relationship between a residual enzyme activity and the development of lysosomal 
storage diseases. According to this model there is a critical threshold value for the 
residual activity necessary to maintain a steady state substrate concentration within the 
lysosome. When the residual enzyme activity falls below this level, the substrate starts 
to accumulate at a constant rate, which depends linearly on the amount of residual 
activity. This model could explain that for individuals with a low ARSA activity, close 
to the threshold limit, a small variation in ARSA activity in the lysosome, even if 
temporary, could lead to an irreversible accumulation of sulfatide with possible clinical 
implications. 
1.8.5. Origin and frequency of low ARSA activity alleles 
The low ARSA activity alleles 2417G/ 3352G, 2417G/ 3352A and 2417A/ 
3352G have very different frequencies in different populations (see graphics 1 and 2). 
The 2417G/ 3352A allele seems to be very frequent, presenting frequencies as high as 
44% in some South African tribes (Ricketts et al, 1996). On the contrary, the allele 
2417A/ 3352G seems to be very rare, since only five non-related cases have been 
described worldwide (Barth et al, 1994; Leistner et al, 1995; Ricketts et al, 1996; Gort 
et al, 1999). Interestingly, the frequencies of alleles 2417G/ 3352G and 2417G/ 3352A 
seem to be inversely correlated in Africans/ Asians (high frequency of 2417G/ 3352A 
allele, 2417G/ 3352G allele almost non-existing) and Europeans/ Indians, with a similar 
40 
General Introduction 
high combined frequency in both groups of populations (Ott et al, 1997). Once again, 
this could indicate some selective advantage for low ARSA activity alleles. 
Frequency determination and haplotype analysis in different populations raised 
several hypotheses regarding the order of appearance of the alterations that characterise 
low ARSA activity alleles and its appearance as single or recurrent events (Zlotogora et 
al, 1994a; Ott et al, 1997). 
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Graphie 1 - Frequency of ARSA allele 2417G/ 3352G. 
(1) Ricketts et al, 1996 (2) Ott et al, 1997 (3) Bognar et al, 2002 (4) Lugowska et al, 2000 (5) 
Pedron et al, 1999 (6) Gort et al, 1999 (7) Zlotogora et al, 1994a (8) Nelson et al, 1991(9) 
Regis et al, 1996 (10) Emre et al, 2000 (11) Barth et al, 1994. 
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Graphie 2 - Frequency of ARSA allele 2417G/ 3352A. 
(1) Ricketts et al, 1996 (2) Ott et al, 1997 (3) Bognar et al, 2002 (5) Pedron et al, 1999 (6) 
Gort et al, 1999 (7) Zlotogora et al, 1994a (8) Nelson et al, 1991 (11) Barth et al, 1994. 
The doubly mutated ARSA-PD allele seems to be associated with a highly 
conserved haplotype, which together with its high frequency in Europeans and its 
absence in non-Europeans, strongly suggests a single ancient origin posterior to the 
divergence of European and Asian populations. The occurrence of the N350S mutation 
in this haplotype would have had to occur first and before the divergence of the African 
and non-African lineages. In the case of the singly mutated alleles, their identification 
on divergent haplotypes suggests the existence of "de novo" mutation events (Ott et al., 
1997). 
42 
General Introduction 
1.9. Molecular characterisation of MLD 
At the molecular level, MLD is very heterogeneous. Approximately ninety 
MLD-causing mutations have been described in the ARSA gene (von Figura et al, 2001 
and www.hgmd.org.), most of these mutations being present in a single family. 
Missense mutations are the most frequent type of alterations in the ARSA gene. Three 
nonsense mutations, ten small deletions, one inversion and seven nucleotide 
substitutions originating altered splicing were also described. To date, no gross 
alterations were described in this gene and none of the mutations reported so far affects 
the amino acid residues thought to be part of the enzyme's active site (see Figures 3, 5 
and 6 and Table 1). Several amino acid substitutions in the ARSA gene were found to 
be polymorphic, they do not lead to a decrease in the enzyme activity and they can be 
found in the general population; examples of these are alterations L76P (Berger et al, 
1996), W193C (Polten et al, 1991), T391S (Polten et al, 1991), A464V (Berger et al, 
1999), and R496H (Ricketts et al, 1998). This fact clearly elucidates the need to prove 
the causality of new mutations. In most cases, expression studies were performed to 
exclude the possibility of novel mutations being polymorphisms, but only in few cases 
the mutated enzymes were further characterised (see Figure 6). 
Several mutations have been described in the background of the ARSA-PD 
alleles (Zlotogora et al, 1995; Regis et al, 1998; Gieselmann et al, 1991). Thus, the 
genetic determination of ARSA-PD alleles can be helpful as a complement of the 
biochemical diagnosis of MLD, but care has to be taken because the presence of ARSA-
PD mutations does not exclude the presence of causal MLD mutations. 
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Three different mutations seem to be relatively frequent among Europeans: 
mutation IVS2+1G>A, which is the causal mutation of allele I, mutations P426L (allele 
A)andI179S. 
The allele I (Polten et al, 1991) is characterised by four different alterations. 
Two of these substitutions (W193C and T391S) were shown to be polymorphisms that 
can be found in healthy individuals and whose introduction in ARSA cDNA does not 
affect the enzyme activity. Another alteration in intron 7 (g2842c, GeneBank sequence 
X52150) can also be found in normal individuals. The fourth alteration (IVS2+1G>A) 
destroys the splice donor site at the 3' exon/ intron border of exon 2. Patients 
homozygous for this alteration do not produce ARSA mRNA. The three polymorphic 
alterations define an haplotype that is in complete linkage disequilibrium with the 
causal alteration, thus raising the possibility of a common origin for this allele 
(Zlotogora et al, 1994b). Allele I presents different frequencies in different European 
populations of MLD patients (25 - 43%), (Polten et al, 1991; Gieselmann et al, 1991; 
Barth et al, 1993a; Regis et al, 1996; Gort et al, 1999). 
44 
General Introduction 
MGAPRSLLLA LAAGLAVARP PNIVLIFADD 
cxl 
LGYGDLGCYG 
S 
41 HPSSTTPNLD QLAAGGLRFT DFYVPVSLCT 
P 
PSRAALLTGRex2 
81 
LPVRMGMYPG VLVPSSRGGL PLEEVTVAEV LAARGYLTGM 
L W D ANL D R 
Q F V 
121 
AGKWHLGVGP EGAFLPPHQG FHRFLGIPYS HDQGPCQNLTex3 
S PS 
L 
G L YHDR 
161 
CFPPATPCDG GCDQGLVPIP LLANLSVEAQ PPWLPGLEAR 
R N Y S H T X 
201 
YMAFAHDLMA DAQRQDRPFF LYYASHHTHY 
PY4 
PQFSGQSFAE 
C V V Y T 
241 RSGRGPFGDS LMELDAAVGT LMTAIGDLGL LEETLVIFTA 
HR Y K H M 
C 
ex5 
281 DNGPETMRMS RGGCSGLLRC GKGTTYEGGV REPALAFWPG 
Y P C 
H 
Y S VS QD T X 
ex6 
321 HIAPGVTHEL ASSLDLLPTL AALAGAPLPN VTLDGFDLSP 
I V 
361 
LLLGTGKSPR QSLFFYPSYP DEVRGVFAVR 
ex7 
TGKYKAHFFT 
N W L K Q W Y 
Q Q 
401 
QGSAHSDTTA DPACHASSSL TAHEPPLLYD LSKDPGENYN 
II L P 
441 LLGGVAGATP EVLQALKQLQ LLKAQLDAAV 
exR 
TFGPSQVARG 
481 
EDPALQICCH PGCTPRPACC HCPDPHA 
X H 
Figure 5 - Amino acid substitutions reported in the ARSA polypeptide. The exons with an 
even number are represented in bold. Amino acid numbering is indicated in the left (adapted 
from von Figura et al. (2001) and www. hgmd. org). 
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Figure 6 - Mutations in the ARSA gene. Distribution along the ARSA gene of the amino acid 
substitutions resulting from missense mutations proved to be causal by expression studies 
(upper part of the ARSA gene picture) and of the small deletions and alterations leading to 
splicing alterations (lower part of the ARSA gene picture). Missense mutations originating an 
enzyme with residual activity are underlined. *Mutations that were found in the ARSA-PD 
allele background. TMutations that were further characterised, all these mutations were found to 
originate enzymes with a reduced half-life. ^Mutations originating the protein's retention in the 
ER. More detailed description and references for these mutations can be found in Table 1. 
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Table 1 - Mutations reported in the ARSA gene. 
Mutation Exon 
Sequence 
alteration Population Reference 
Missense mutations proved by expression studies 
R84Qa Exon 2 400G>A European Kappler, 1992; Berger, 1997 
G86D Exon 2 406G>A Muslin Arab Heinish, 1995; Hermann, 2000 
S96Fa Exon 2 4 3 6 0 T European Gieselmann, 1991; Berger, 1997 
S96L Exon 2 435/436TOCT Muslin Arab Heinish, 1995 
G99D Exon 2 445G>A Japanese Kondo, 1991; Eto, 1993 
G122S Exon 2 513G>A Japanese/ European Honke, 1993; Kappler, 1994 
L135P Exon 2 553T>C European Gomez-Lira, 1998 
P136L Exon 2 5 5 9 0 T Jewish Kafert, 1995 
R143G Exon 2 5 7 6 0 G Vietnam Arbour, 2000 
Q153H Exon 2 608G>C Japanese Tsuda, 1996 
G154D Exon 3 724G>A European Kappler, 1994 
P167R Exon 3 763C>G European Kappler, 1994 
I179S Exon 3 799T>G European Fluharthy, 1991 
Q190H Exon 3 833G>C Muslin Arab Heinish, 1995 
Y201C Exon 3 865A>G European Hermann, 2000 
A212V Exon 3 898G>T European Barth, 1993b; Coulter-Mackie, 1997a 
A224V Exon 3 934C>T European Barth, 1993b 
G245R Exon4 1070G>A Japanese Hasegawa, 1993 
E253K Exon4 1094G>A European Regis, 2002 
D255H Exon4 1100G>C European Lissens, 1996 ; Hermann, 2000 
T274M Exon4 11580T Lebanese Harvey, 1993; Hess, 1996a 
S295Y Exon 5 15330A European Barth, 1993b 
L298S Exon 5 1542T>C Japanese Kurosawa, 1998 
G308V Exon 5 1572G>T Japanese Tsuda, 1996 
G309S Exon 5 1574G>A European Kreysing, 1993 
E312D Exon 5 1585G>T European Hermann, 2000 
D335Vb Exon 6 1743A>T European Hess, 1996a; Schestag, 2002 
R370Wb Exon 7 2093OT Christian Arab Heinish, 1995; Schestag, 2002 
R370Qb Exon 7 2094G>A Jewish von Figura, 2001; Schestag, 2002 
P377L" Exon 7 2 1 1 9 0 T Habbanite Jewish Zlotogora, 1995 
D381V Exon 7 2131G>A European von Figura, 2001 
E382K Exon 7 G2133>A European Barth, 1993b 
R390Q Exon 7 2158G>A unknown Coulter-Mackie, 1998 
H397Y Exon 7 2 1 7 8 0 T unknown Coulter-Mackie, 1998 
T409I Exon 8 2330OT Japanese Hasegawa, 1994 
P426L Exon 8 2 3 8 1 0 T European Polten, 1991 
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Mutation 
Exon/ 
Intron Sequence alteration Population Reference 
Nonsense mutations 
W193X Exon 3 
W318X Exon 5 
Q486X Exon 8 
842G>A 
1603G>A 
2560OT 
European 
Vietnam 
European 
Gort, 1999 
Arbour, 2000 
Draghia, 1997 
Small deletions and insertions 
5delG Exon 1 ATGGgGGCA European Berger, 1999 
102del8pb Exon 1 GGGgacctgggCTG European Draghia, 1997 
386delC Exon 2 GGCcTGCCC European Gort, 1999 
447delC Exon 2 GGCcTG European Kreysing, 1993 
540dell2pb Exon 2 TGagggggccttccTG European Luyten, 1995 
2180del3pb Exon 7 CACttcTTC European Gieselmann, 1994 
2320del9pba Exon 8 CACagtgataccACT European Regis, 1998 
2324delAT Exon 8 AGTGatACC European Regis, 1995 
2504delllpb Exon 8 TTAGAcgcagctgtgaCC European Bonne, 1991 
435TC-CT Exon 2 TC-CT Arab Heinish, 1995 
Mutations originating splicing alterations 
IVS1-2A>G intron 1 366A>G Japanese Kurosawa, 1998 
IVS2+1G>A intron 2 609G>A European Polten, 1991 
IVS3+1G>A intron 3 942G>A European Barth, 1995 
IVS4+1G>A intron 4 1186G>A Navarro Indian/ 
Alaskan Eskimo 
Pastor-Soler, 1994 
Pastor-Soler, 1995 
IVS6-12C>G intron 6 2079G>C European Gort, 1999 
IVS7+1G>A intron 7 2194G>A European Fluharthy, 1991 
IVS7+22C>T intron 7 2 2 1 5 0 T Japanese Hasegawa, 1994 
T409I exon 8 2330OT Japanese Hasegawa, 1994 
a Mutations identified 
intramolecular salt bridge that 
and www.hgmd.org. 
in a ARSA-PD associated allele. Residues Asp335 and Arg370 form an 
is destroid by these mutations. Data according to von Figura et al. (2001) 
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The allele A (Polten et al, 1991) is characterised by one single mutation in exon 
8, which changes proline 426 into leucine (P426L). ARSA cross-reacting material and 
activity are absent in cultured fibroblasts of homozygous patients, but can be restored 
by treatment with a cysteine proteinase inhibitor (von Figura et al, 1983; Polten et al, 
1991). This protein is synthesised in normal amounts, has enzymatic activity and is 
correctly targeted to the lysosome, where it is rapidly degraded (von Figura et al, 1983; 
Gieselmann et al, 1994). A recent publication by von Bulow et al. (2002), explains its 
instability in lysosomes by its defective oligomerization. This allele presents 
frequencies between 1.9 and 30% in different European populations of MLD patients 
and is frequently associated with late onset forms of MLD (Gieselmann et al, 1991; 
Polten et al, 1991; Barth et al, 1993a; Regis et al, 1996). 
Mutation I179S represents 2-12% of the MLD causal mutations in Europe 
(Fluharty et al, 1991; Berger et al, 1997; Gomez-Lira et al, 1998; Halsall et al, 1999). 
The expression of an ARSA cDNA with this mutation, in BHK cells, produces only 5% 
of the enzyme activity measured from the expression of wild type ARSA (Fluharty et 
al, 1991). This mutation was always observed in patients with late onset disease and 
interestingly homozygosity for this mutation was never reported (von Figura et al, 
2001). 
Baumann et al (2002), recently reported a study of 12 adult patients among 
whom they could distinguish two different adult clinical forms. Some patients presented 
mainly motor symptoms with central nervous system motor signs and peripheral 
neuropathy. Mutation P426L was frequently found in these patients. Other patients 
presented a psycho-cognitive form of the disease, with onset characterised by 
behavioural abnormalities including mood alterations, peculiar social reactions and 
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progressive mental deterioration. The neurological involvement could be observed only 
a few years after the onset. Among these patients, I179S was the most frequent 
mutation. 
Some other mutations are relatively frequent among non-European populations. 
Kondo et al. (1991) reported mutation G99D in an adult Japanese patient. This mutation 
seems to represent 45% of the MLD causal alleles in Japan (Kurosawa et al, 1998). 
Northern blotting analysis revealed a normal amount of ARSA mRNA in patients' 
fibroblasts. The introduction of this mutation in ARSA cDNA leads to a complete 
abolishment of ARSA activity (Kondo et al, 1991). 
Mutation IVS4+1G>A was found to be frequent among the Navajo Indian 
population and in the Southern Alaskan Eskimos (Pastor-Soler et al, 1994; Pastor-Soler 
et al, 1995). By Northern blotting analysis negligible amounts of ARSA mRNA were 
found, a deletion of all exon 4 with a new reading frame and a stop codon at exon 5, 
occurs. 
Another mutation found with high frequency in a particular population is the 
mutation P377L, which was found in a PD allele background, in the Habbanite and 
Yemenite Jews communities (Zlotogora et al, 1995). The ARSA protein with this 
mutation is retained in an early biosynthetic compartment and does not reach the 
lysosome (Gieselmann et al, 1994). 
In Australian and Australian Lebanese patients, mutation T274M represents 20% 
and 85% of the MLD causal mutations, respectively (Heinisch et al, 1995; Harvey et 
al, 1993). Low amounts of enzyme activity can be detected in cells expressing the 
T274M substituted cDNA. The mutant enzyme has a specific activity of 35% but the 
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majority of it seems to be rapidly degraded in an early biosynthetic compartment (Hess 
etal, 1996a). 
1.10. Genotype-Phenotype correlation in MLD 
Polten et al (1991) tried to establish a genotype-phenotype correlation in MLD. 
According to the authors, there are two kinds of alleles in MLD: null alleles and alleles 
that originate low amounts of residual enzyme activity (R alleles). Homozygosity for 
null alleles always cause the most severe late infantile form of the disease and two R-
type alleles usually originate the milder adult form. One copy of an R allele should 
mitigate the course of the disease (Polten et al, 1991). 
In spite of this theory still being accepted in a general way, the initial hope that it 
would be possible to make straightforward genotype-phenotype correlations, predicting 
the clinical outcome from the genotype analysis, did not come through. Unknown 
factors, genetic or environmental, other than the ARSA gene mutations must contribute 
to the MLD phenotype. Not only is difficult to predict the clinical course of the disease 
in patients with one R allele, as they can present any of the three MLD clinical forms, 
but also intrafamilial heterogeneity was found regarding the age of onset and severity of 
the disease (for review see von Figura et al, 2001). 
1.11. Animal models for MLD 
Animal models can be very important to the study of pathogenesis and 
approaches to therapy of lysosomal storage disorders. 
The only animal model for MLD are the ARSA-deficient mice, generated by 
homologous recombination in embryonic stem cells (Hess et al, 1996b). There are no 
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natural animal models. Complete ARSA activity absence and sulfatide storage in 
several organs, including the brain, could be found in the ARSA-deficient animals. 
Thus, biochemically they resemble the late infantile form of MLD. Various neurological 
and behavioural abnormalities can be observed in ARSA-deficient mice, but they have a 
phenotype much milder than it would be expected, with neurophatological alterations 
progressing slowly. This is probably related to the absence of demyelination in the 
central nervous system, although a variety of pathological alterations can be found in 
the nervous system. The mice phenotype thus seems to resemble early stages in the 
human disease; neuromotor alterations, impaired learning and memory and decline in 
brainstem auditory-evoked potentials could be observed (Hess et al., 1996b; 
Gieselmann et al., 1998; D'Hooge et al., 1999a; D'Hooge et al., 1999b; D'Hooge et al., 
2001;Schotte/a/.,2001). 
1.12. Therapy 
Different potential therapeutic strategies have emerged recently for Lysosomal 
Storage Disorders (LSD). They are based on two major therapeutic approaches: enzyme 
supplementation, which can be achieved by enzyme replacement, bone marrow 
transplantation or gene therapy, and substrate deprivation. 
Although enzyme replacement therapy is already approved or under clinical 
studies for several lysosomal storage disorders (Beutler et al., 1997; Schiffmann et al., 
2000; Kakkis et al., 2002; van den Hout et al., 2001), this is an extremely expensive 
therapy and the administrated enzyme has no capacity of crossing the blood brain 
barrier and get into the brain, which means that it has no efficiency in LSD with central 
nervous system involvement, as is the case of MLD. 
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Substrate deprivation therapy is also under development for several LSD (Piatt, 
et al, 1997; Piatt et al, 2001; Abe et al, 2000; Jeyakumar et al, 1999), and more 
selective and potent inhibitors of glycosphingolipid synthesis are being investigated 
(Lee et al, 1999; Abe et al, 2000). 
Since the inhibitors that have been used have the capacity of crossing the blood 
brain barrier, this seems to be a strategy whit great potential for LSD with central 
nervous system involvement. However, a major limitation results from the fact that 
these inhibitors act on the enzyme implicated in the glucosylceramide synthesis (Piatt et 
al, 1994) and thus they are only efficient in the LSD in which the accumulated 
substrate derives from this glycosphingolipid. So, in spite of its potential use in other 
LSD, this kind of therapy also does not look promising in the case of MLD. 
Several observations indicated the bone marrow transplantation (BMT) as an 
important option for MLD therapy. As with lysosomal enzymes, ARSA can be secreted 
by one cell and internalised and delivered to the lysosomes of a neighbour cell through 
the mannose-6-phosphate receptors on the cell surface (Neufeld et al, 1991). It has also 
been demonstrated that even very low amounts (5%) of endocytosed enzyme can be 
sufficient to correct the metabolic defect associated with MLD (Leinekugel et al, 1992; 
Penzien et al, 1993). The ARSA would have to be delivered to the glial cells in the 
brain, which are not accessible to plasma enzymes due to the blood-brain-barrier, but it 
had been shown that bone marrow derived monocytes/macrophages can cross the blood 
brain barrier and became perivascular macrophages and microglia (Krivit et al, 1995; 
Krivit et al, 1999). It thus seemed that normal monocytes of a donor bone marrow 
could originate in a MLD patient, resident microglial cells secreting normal ARSA and 
delivering it to the ARSA-deficient glial cells. With these observations, bone marrow 
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transplantation or bone marrow transplantation combined with gene therapy, were thus 
considered potentially useful therapeutic approaches for LSD with central nervous 
system manifestations, as is the case of MLD. 
Nevertheless, it was recently reported that both macrophages and microglial 
cells secrete lysosomal enzymes that lack Man-6-P residues, which means that another 
mechanism, independent of Man-6-P-dependent secretion and recapture of lysosomal 
enzymes would have to be responsible for the therapeutic effects of BMT in brain 
(Muscholétfa/.,2002). 
Although several MLD patients had bone marrow transplantations, it is still not 
defined whether this is a valuable therapeutic option or not. The data available at the 
moment seem to indicate that in the case of symptomatic late infantile patients it is not 
effective, but regarding the cases of pre-symptomatic late infantile patients and late 
onset patients different results have been obtained. A follow-up of a significant number 
of transplanted patients has to be made before definitive conclusions can be reached (for 
reviewing see von Figura et al, 2001). 
Two different groups attempted to correct ARSA-deficient mice symptoms by 
gene therapy. Matzner et al (2000, 2002), transplanted ARSA-deficient mice with 
genetically modified bone marrow cells overexpressing ARSA from a retroviral vector. 
The authors could observe a sulfatide storage reduction in liver but not in kidney and 
brain, this is in spite of the high enzyme activities in these tissues, resulting from a 
sustained high expression. Only a minor improvement in the neurological symptoms of 
treated mice was observed. 
Another group (Consiglio et al, 2001) reported the protection of ARSA-
deficient mice from neuropathology using direct gene delivery into the central nervous 
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system by lentiviral vectors. Therefore, gene therapy remains a promise, but the 
experimental support for its efficiency is very limited and it can not be forgotten that the 
MLD mouse pathology only in part resembles human pathology, progressing more 
slowly and with less severity (Hess et al, 1996b). 
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GENERAL AIMS AND OUTLINE OF THIS THESIS 
The general aims of this thesis were: 
1 - To define the genetic epidemiology of MLD and ARSA-PD in Portugal. 
2 - To study the impact of ARSA mutations in the structure, function and 
localization of the enzyme. 
3 - To contribute to the establishment of a genotype/ phenotype correlation in 
MLD patients. 
4 - To investigate the association of ARSA-PD with schizophrenia. 
Before the beginning of this work, nothing was known regarding the genetic 
epidemiology of both ARSA deficiencies (MLD and ARSA-PD) in Portugal. To 
address this question we started by the definition of the mutation profile of the 
Portuguese MLD patients and by the analysis of the haplotype associated with each 
mutation. In this severe pathology, without an effective therapy, the pre-natal diagnosis 
and the identification of carriers within the families is very important since it allows the 
prevention of this disease. The molecular diagnosis is fundamental to the identification 
of hétérozygotes and to exclude the existence of ARSA-PD, which represents a problem 
for the biochemical diagnosis of MLD based on the ARSA activity determination. The 
identification of the mutations associated with the different MLD clinical forms further 
contributes to the establishment of genotype-phenotype correlations that might be 
helpful to predict the age of onset and progression of the disease when associated with 
particular mutations. These results are presented in Chapter 1 - Section 1A.1 (Marcão et 
al, Human Mutation (1999) 13(4): 337-8) and Chapter 1 - Section 1A.2 (Marcão et al, 
manuscript in preparation). 
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Three different alleles have been found to be associated with ARSA-PD, they 
can present very different frequencies in different populations and several hypotheses 
regarding their spatial and temporal origin remain speculative. Considering the 
interference of this condition in the MLD biochemical diagnosis and the possibility of 
its implication in the pathogenesis of some MLD non-related pathologies, we decided to 
determine the frequency and haplotype of the ARSA-PD associated alleles in the 
Portuguese population. These studies were important at a public health point of view 
and at a populations' genetics study point of view. The results are presented in Chapter 
1 - Section IB (Marcão et al, Mol Genet Metab (2003) 79(4): 305-307). As a first 
attempt to analyse the possibility of an increased risk of ARSA-PD individuals to 
develop schizophrenia, the frequency of the ARSA-PD alleles was also determined in a 
group of schizophrenic patients. The preliminary results on this subject are also 
presented in Chapter 1 - Section IB. 
Regardless of the three-dimensional structure of ARSA being resolved and the 
amino acids constituting the active site of the enzyme being identified, it is still not easy 
to predict for certain the effect of a particular alteration in the enzyme's structure and 
function. The identification of several non-conservative amino acid substitutions that do 
not lead to a decrease of ARSA activity, clearly illustrates the importance of doing 
expression analysis of every novel alteration found in the ARSA coding gene, especially 
in the case of missense mutations. These studies not only contribute to the elucidation of 
a genotype-phenotype correlation in MLD, but can also reveal some important amino 
acid residues or domains of the protein. The results of the expression of three novel 
mutations in the ARSA codifying gene are presented in Chapter 2 - Section 2A.1 
(Marcão et al, Am J Med Genet (2003) 116A(3): 238-42) and Chapter 2 - Section 2A.2 
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(the results presented in this section of Chapter 2 are part of a paper resulting from a 
collaboration with two other groups and that is submitted for publication). 
In the case of multimeric lysosomal enzymes like ARSA, the reason for the low 
in vivo activity associated with a specific mutation is not always easy to identify. The 
residual specific activity of the mutated enzyme is not the only important parameter. 
The enzyme has to be activated in the ER through a posttranslational modification 
common to all sulfatases, it has to be correctly folded, in order to escape to the ER 
quality control machinery, and it has to be able to reach the Golgi. In the Golgi, it has to 
be correctly phosphorylated, in order to be recognized by the Man-6-P receptors and to 
be correctly targeted to the lysosomes. Once in the lysosome, the enzyme has yet to be 
able to octamerize, otherwise it is rapidly degraded by the lysosomal proteases. The 
biochemical characterization of each mutation, including the analysis of these different 
steps, can thus contribute to a more general understanding of the normal cellular 
processes of posttranslational modification, folding, traffic through the cell, targeting to 
the lysosome, stabilization and activity in the lysosome of the lysosomal soluble 
enzymes. Additionally, these studies contribute to the understanding of the general 
picture of the cell functioning in pathological situations, which is essential for the 
development of new therapeutic strategies for lysosomal storage disorders. In this 
perspective, we studied the effect of three novel missense mutations on the stability and 
correct targeting of ARSA to the lysosome (Chapter 2 - Section 2A) and the effect of 
two of these mutations on the quaternary structure of ARSA (Chapter 2 - Section 2B, 
Mar cão et al, Biochem Biophys Res Commun (2003) 306(1): 293-7). 
59 
CHAPTER 1. GENETIC EPIDEMIOLOGY OF ARSA 
DEFICIENCIES IN THE PORTUGUESE POPULATION 
lA. MLD IN PORTUGAL 
l A . l . IDENTIFICATION OF NEW MOLECULAR LESIONS 
1A.2. MUTATION PROFILE OF MLD PATIENTS 
IB. ARSA-PD ASSOCIATED ALLELES IN THE PORTUGUESE 
POPULATION 
IA. MLD IN PORTUGAL 
1 A.l. IDENTIFICATION OF NEW MOLECULAR 
LESIONS 
HUMAN MUTATION Mutation in Brief #232 (1999) Online 
MUTA TION IN BRIEF 
Metachromatic Leucodystrophy in Portugal-
Finding of Four New Molecular Lesions: C300F, 
P425T, g.ll90-1191insC, and g.2408delC 
Ana Marcão, Olga Amaral, Eugenia Pinto, Rui Pinto, M.C. Sá Miranda 
Department of Enzymology, Instituto de Genética Médica Jacinto de Magalhães; Praça Pedro Nunes 84, 4050-
Oporto, and Department of Genetic Neurobiology, Instituto de Biologia Molecular e Celular; Rua Lampo Alegre 
823, 4150-Oporto, Portugal. 
Correspondence to M.C. Sá Miranda 
Department of Enzymology, Instituto de Genética Médica Jacinto de Magalhães 
Praça Pedro Nunes 84, 4050-Oporto, Portugal 
Telephone: 351-2-6092404 or 6074900; telex: 351-2-201177; fax: 351-2-6099157 or 6092404. 
Contract grant sponsor: FCT-Portugal; Contract grant number: PRAXIS XXI/BD/16058/98. 
Communicated by Haig H. Kazazian 
ABSTRACT 
The mutation identification rate achieved in the study of Portuguese MLD patients was 
found to be extremely high (100%), thus revealing the power of the association of vertical 
and horizontal PCR-SSCA The identification of new mutations adds to the large number of 
mutations already described to be associated to MLD. Nevertheless, mutation g.l238G>A 
has been found in most of the Portuguese patients, either in homozygosity or heterozygosity, 
suggesting this mutation to be more common in Portuguese patients than in patients with 
other ethnic backgrounds. Two new missense mutations (C300F and P425T) were found to 
be associated to late infantile and juvenile forms, respectively. Two novel microlesions 
(g.H90-1191insC, g.2408delC) were identified in two late infantile patients. It should be 
noted that both C300F and g.2408delC were detected in homozygosity. 
The approach used and the results here presented may provide useful information for the 
study of other MLD patients, as well as new insights about the effect of mutations, such as 
C300F, in the structure/function of ARSA. © 1999 Wiley-Liss, Inc. 
KEY WORDS: Metachromatic leucodystrophy; Portuguese population; ARSA 
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INTRODUCTION 
Metachromatic Leucodystrophy (MLD, MIM# 250100) is an autosomic recessive disorder (estimated 
frequency of 1:100,000) usually caused by deficient arylsulfatase A (ARSA, EC 3.1.6.8) and by the 
intralysosomal accumulation of its substrate, cerebroside sulfate. Three major clinical forms are generally 
considered according to the age of onset (late infantile, juvenile and adult forms). The late infantile form is the 
most frequent clinical form of MLD, and is characterized by onset between ages of fifteen months and two years 
of age (Kolodny and Fluharty, 1995). 
Located on chromosome 22ql3, the ARSA gene spans 3.2 kb (with a 1521 bp cDNA), comprises 8 exons 
(Kreysing et al., 1990) and encodes a 507 aa protein (Stein et al., 1989). Of the numerous point mutations 
described in the ARSA gene, very few ARSA mutations are public. The two most common ARSA mutations are 
mutation g.l238G>A (designated as allele "I", MIM# 250100.0003) and mutation P426L (also called allele "A", 
MIM# 250100.0004). Both of these mutations are known to account for about 50% of all MLD causing alleles 
(Poltenetal, 1991). 
Despite the high frequency of allele g.l238G>A (79%) among unrelated Portuguese MLD patients (Amaral et 
al., 1998) some heterogeneity has been found. Extensive scanning of the ARSA exons and flanking regions, by 
SSCA allowed full characterization of the Portuguese MLD patients and resulted in the detection of four new 
molecular lesions, two in homozygosity and two in compound heterozygosity. Since the lowest rate of MLD allele 
detection seems to be among late infantile patients (Berger et al., 1997), the approach pertaining to the 
identification of these novel mutations associated with this form of the disease, may provide new clues for the 
molecular analysis of other European MLD populations. 
MATERIAL AND METHODS 
Patient description 
The patients presented in this study originate from various regions of Portugal. All three late infantile patients 
presented onset between 12 and 24 months of age with death arising before seven years of age. With regard to the 
juvenile patient, symptoms were detected at age five and death occurred at thirteen years of age. Two of the cases 
here presented (patients C and D), were only clinically and biochemically diagnosed, no biological materials were 
available at the time of the molecular characterization. In both cases the molecular studies were performed on the 
biological material from both parents. Whenever possible the patients' parents were also studied in order to 
corroborate the patient results. In all cases, samples were obtained with informed consent. 
Population studied in the screening of the novel mutations 
Blood samples from fifty healthy individuals were randomly collected among blood bank donors. 
Biochemical studies 
Patients were biochemically diagnosed by ARSA activity determination in leucocytes (Baum et al., 1959; Lee-
Vaupel and Conzelmann, 1987) and by the study of sulfatide excretion in urine (unpublished method). 
Molecular Studies 
Genomic DNA was extracted from frozen leucocyte pellets, fibroblasts or buffy coats following standard 
methods. 
Patients, or their parents when biological material from the patients was not available, were first screened for 
the presence of the two most frequent MLD causal mutations by Mva I or by ASOH (in the case of mutation 
g.l238G>A and P426L, respectively). The PCR conditions used for the amplification of various regions of the 
ARSA gene were as indicated in table 1. The ARSA haplotype was also determined (Zlotogora et al. 1994). 
The application of both horizontal (Amaral et al., 1996) and vertical (Ribeiro et al., 1996) SSCA resulted in 
the identification of 100% of the patients' alleles. Samples presenting abnormal migration patterns were 
submitted to direct sequencing of asymmetric PCR generated products. In all cases different PCR samples were 
sequenced to confirm the reproducibility of the results and when possible the alteration was confirmed by 
restriction endonuclease digestion. Whenever possible the findings were corroborated by the analysis of the 
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patients' parents. In the two cases in which no biological material was available from the patients, the parents 
were exhaustively tested by SSCA. 
Most reagents were from Boehringer Mannheim (GmbH, W. Germany), Pharmacia Biotech (Upsalla, 
Sweden), PE Applied Biosystems or from Sigma (Spain). 
RESULTS 
As shown in table 2, patients A and D were compound hétérozygotes for g.l238G>A and P426L (late infantile 
and juvenile patients, respectively), whereas patients B and C did not present either mutation. 
Examination by PCR-SSCA and sequencing of samples presenting abnormal migration patterns resulted in the 
detection of four new mutations (table 2). 
The g.3006C>A transversion (P425T) was confirmed by restriction endonuclease Bmy I digestion. In the case 
of the C300F mutation (patient C) a different approach was followed, a mismatched primer was designed in order 
to create a site for the restriction endonuclease Sfu I, in the presence of this mutation (table 1). 
The screening of mutations C300F (Sfu I) and P425T (Bmy I), in a sample of 100 alleles indicated that these 
mutations were not polymorphic. 
It would be interesting to further study the new mutations presented in this paper, unfortunately the lack of 
immortalized biological materials from most of these patients makes it difficult. 
DISCUSSION 
Late infantile patients 
The identification of C300F in both parents of patient C indicated that this patient must have been 
homozygous for this novel mutation. The fact that C300 is conserved among murine and human ARSA (Kreysing 
et al., 1994) suggests that this residue is important for the structure and function of the protein. With the 
publication of ARSA's crystal structure it is possible to see that this mutation leads to the disruption of the 
disulfide covalent bond between amino acids 300 and 414, linking the two major and minor P-sheets (Lukatela et 
al., 1998). The finding of this novel mutation in the non-consanguineous parents of patient C indicated that this 
might be a rare but not private mutation. 
The identification of a novel insertion (g.l 190-1191 insC) in exon 2 of patient A contributes to the large 
number of mutations already described in this exon. The resulting frameshift leads to the appearance of a stop 
codon in exon 3, this patient bears another null allele, allele g.l238G>A. 
Patient B, homozygous for a novel microdeletion in exon 6 (g.2408delC), was the daughter of consanguineous 
parents (first cousins) thus suggesting a private mutation. This deletion leads to the appearance of a stop codon in 
exon 8, predicting the truncation of the protein about 84 aminoacids before its carboxi terminus. The 
identification of this nonsense mutation in homozygosity, in a late infantile patient, indicates that this is also a 
null allele. 
Juvenile Patient 
Patient D was never studied at the molecular level since biological material was unavailable. The study of the 
parents revealed that the father carried allele P426L, while the mother carried mutation P425T.This seems to be a 
novel and causal mutation, this proline is preserved in the murine ARSA gene (Kreysing et al., 1994), in the sea 
urchin and sulfatases A, B and C (Kolodny and Fluharty, 1995). In this case, and according to the ARSA crystal 
structure, the regulation of dimer octamer association is probably impaired and must result in rather detrimental 
effects at the enzyme level. 
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SUMMARY 
In this work we report the identification of four new highly deleterious ARSA mutations found in Portuguese 
MLD patients: two microlesions (in late infantile patients) and two missense lesions (in a homozygous late 
infantile patient and in a juvenile patient with one low residual activity allele). 
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Table 1: PCR primers and conditions for the amplification of different ARSA fragments. 
Exon included in the 
PCR fragment 
Size of PCR 
product 
Sequence of oligonucleotide primers (5'-3') PCR conditions 
( 30 cycles ) 
Exon 1 328 bp AGCCTGCTGGAGCCAAGTA 
AGGAAAGGGATGGAGGGTC 
l ' -94°C 
5'-66°C 
Exon 2 362 bp TCAGGGACTCTGTGACTTGTC 
TGAGGGCTGGGCTGGCAGGTG 
40"-94°C 
2'30"-66°C 
Exon 3 269 bp CCCAGCCCTCACGGCAGCT 
GTTGGGCCAAGATCACTTA 
40"-94°C 
2'30" - 66 °C 
Exon 4 323 bp ACGTAAGTGATCTTGGCCC 
GCAAGCAGCTGAACTGCAA 
40"-94°C 
2'30"-66°C 
Exon 5 235 bp TCAGAGGCTGTGGCTCCAT 
CAGTTCGCCATCAAGGTTG 
l ' -94°C 
5' - 66 °C 
Exon 5 (3' end) 116 bp TCAGAGGCTGTGGCTCCAT 
CGTAGGTCGTTCCCTTTCGAa 
35"-94°C 
40"-58°C 
45"-72°C 
Exon 6 217 bp CCTTGATGGCGAACTGAG 
AGGACAGGGGCCAAGGAT 
l ' -94°C 
5'-66°C 
Exon 7 291 bp GGTTCCTGGGTGGGCAAGAAG 
AGGGATCTAGGGCTCCGGGG 
40" - 94 °C 
2'30"-66°C 
Exon 8 (5' end) 309 bp CCTTGCCCTGTGCACAGAA 
GCAGCCAGGATGACAGCAGAT 
40"-94°C 
2'30"-66°C 
Exon 8 (3' end) 304 bp CTGCTCAAGGCCCAGTTAG 
ACCAGCACAGCATTACC 
40"-94°C 
2'30"-66°C 
"The underlined nucleotide represents a mismatch in order to create a Sfu I site in the presence of the mutated 
sequence. 
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Table 2: Summarized characteristics of cases with novel mutations. 
Patient Clinical 
form of 
MLD 
ARSA 
Activity 
(nmol/h/ 
mg) 
Genotype Novel Molecular 
lesion0 
Detection 
method of new 
mutations 
Altered 
exon 
Haplotyped 
Bgll Bam HI BsrI 
A Late 
infantile 
0a g.l238G>A/ 
g.l 190­1191insC 
g.l 190­1191insC 
(Frameshift) 
Vertical SSCA 
/sequencing 
2 (1), (2) (D,(l) (1), (2) 
B Late 
infantile 
0a g.2408delC/ 
g.2408delC 
g.2408delC 
(Frameshift) 
Vertical SSCA 
/sequencing 
6 (2), (2) (0,0) (1),(D 
C* Late 
infantile 
0a C300F/C300F g.2177G>T 
(Cys300Phe) 
Horizontal SSCA 
/Sfu I digestion 
5 (2), (2) (1),(?) (?), (?) 
D* Juvenile 5b P426L /P425T g.3006OA 
(Pro425Thr) 
Horizontal SSCA 
/Bmy digestion 
8 (2), (2) (1),(?) (?), (?) 
♦Biological material from these patients was not available for the molecular studies. The study was done in the 
patients' parents DNA. 
"ARSA activity determined according to Lee­Vaupel M and Conzelmann E, 1987 (reference values in our 
Department: 6­15 nmol/h/mg). 
bARSA activity determined according to Baum et al., 1959 (reference values in our Department : 43­234 
nmol/h/mg). 
'Genomic sequence numbering according to GenBank X52150. 
dHaplotype designation according to Zlotogora et al., 1994. 
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MUTATION PROFILE OF METACHROMATIC LEUKODYSTROPHY IN PORTUGAL: 
COMPARISON WITH OTHER EUROPEAN MLD POPULATIONS 
Marcão A, Pinto E, Silva E, Rocha S, Pinto R, Amaral O and Sá Miranda MC 
Abstract 
Metachromatic Leukodystrophy is an autosomal recessive disorder usually caused by 
deficient Arylsulfatase A (ARSA). In this work, sixteen unrelated Portuguese patients 
with deficient ARSA activity were investigated for molecular lesions in the ARSA 
coding gene. Mutation IVS2+1G>A was found in 60% of the MLD causal alleles, 
suggesting this mutation to be more common in Portuguese patients than in patients 
with other ethnic backgrounds. Its finding at such a high frequency and in linkage 
disequilibrium with its originally described haplotype, supports the idea of a common 
ancient European origin for this mutation. On the contrary, mutation P426L, reported as 
the most frequent MLD mutation among late onset patients, was found in only one 
allele, in one juvenile patient. Six additional molecular lesions were identified by an 
SSCA-sequencing strategy, thus confirming the molecular heterogeneity reported in 
MLD. The ARSA-PD associated alterations were not found in any of these patients. 
Two missense mutations previously described in non-Portuguese patients, I179S and 
D255H, were both found in heterozygosity with allele IVS2+1G>A and associated to 
adult and late infantile MLD, respectively. Two microlesions (c412insC, cl040delC) 
and one missense mutation (C300F) were found to be associated to the late infantile 
form, while another missense mutation (P425T) was found in a juvenile patient. All 
these four mutations were reported for the first time in Portuguese patients, and only 
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mutation c412insC was recently also reported in a Greek patient (Coulter-Mackie et al, 
2003). Some clinical heterogeneity was found among the adult patients having the same 
genotype, even within the same family. Moreover, the patients belonging to two of the 
three families with adult patients do not seem to excrete elevated amounts of sulfatide in 
urine, which also indicates some biochemical heterogeneity. 
Key Words: Metachromatic Leukodystrophy; Portugal; Arylsulfatase A; mutations; 
haplotype. 
Introduction 
Metachromatic Leukodystrophy (MLD, McKusick 250100) is an autosomic 
recessive disorder usually caused by deficient Arylsulfatase A (ARSA, EC 3.1.6.8) and 
characterised by the intralysosomal accumulation of its substrate, 3-O-sulfo-
galactosylceramide (sulfatide). This leukodystrophy presents three major clinical forms 
(late infantile, juvenile and adult), classified according to the age of onset. 
Heterogeneity exists in the age of onset and clinical course of the disease, being 
particularly evident in the adult form (for review see von Figura et al, 2001). 
The ARSA locus is located in chromosome 22ql3, the gene is divided into 8 
exons spanning 3.2 Kb (Kreysing et al, 1990). The cDNA is 1521 bp long and codifies 
a 507 amino acids protein (Stein et al, 1989). Presently, over 90 mutations have been 
described in the ARSA gene as giving rise to decreased enzyme activity (von Figura et 
al, 2001 and www.hgmd.org). The two most common ARSA mutations in European 
populations are mutation IVS2+1G>A (allele I) and mutation P426L (allele A), first 
described as associated with late infantile and adult clinical forms, respectively (Polten 
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et al, 1991). Mutation I179S is the third most common mutation in Europe and has 
been always found associated with late onset clinical forms, even when in 
heterozygosity with null mutations (von Figura et al, 2001). Most of other mutations 
identified in the ARSA coding gene were found in single families or in isolated ethnic 
groups. 
Based on the linkage disequilibrium verified between mutation IVS2+1G>A and 
a single rare haplotype, defined by three intragenic polymorphisms, Zlotogora et al. 
(1994) suggested a common origin for all IVS2+1G>A alleles. This haplotype was later 
extended to other two intragenic polymorphisms by Coulter-Mackie et al (1997). 
In Portugal, MLD has a prevalence of approximately 1: 50 000 (Pinto et al, in 
press). 
In this work we present the results of the molecular study of twenty Portuguese 
MLD patients belonging to sixteen unrelated families. After testing IVS2+1G>A and 
P426L mutations, the application of an SSCA (Single Strand Conformation Analysis)/ 
Sequencing strategy allowed full characterisation of the patients with the detection of 
six additional molecular lesions. Haplotype analysis regarding five intragenic 
polymorphisms was also performed. 
Material and Methods 
Patients 
A total of twenty patients belonging to sixteen unrelated families, and 
originating from various regions of Portugal, were included in this study. Several 
patients (I, K, M, N, O and P) were previously referred in other publications (Alves et 
al, 1986; Marcão et al, 1999). All the late infantile patients (12 unrelated patients) 
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presented a classical clinical evolution with onset occurring around two years of age and 
originated from various regions of Portugal. The juvenile patient (N) was from the 
northern region of Portugal. He started to develop symptoms at 5 years of age and died 
with 13 years of age. Adult patients from families 14 and 15 also originated from the 
north of Portugal, whereas the adult patient T was from Azores. We have no detailed 
clinical information regarding patients from family 15. Patients from families 14 and 16 
first presented with behavioural disturbances, with normal neurological examinations 
and without any motor signs. Progressive intellectual deterioration developed in all of 
them. 
Material 
Oligonucleotides were synthesised by Amersham Pharmacia Biotech (Freiburg, 
Germany). Restriction endonucleases were from New England Biolabs (Frankfurt am 
Main, Germany) or Roche Applied Science (Mannheim, Germany). Taq DNA 
polymerase was from Invitrogen (Groningen, The Netherlands). NuSieve® 3:1 agarose 
was from BioWhittaker Molecular Applications (BMA, Rockland, USA). Other 
reagents were from Sigma (Sigma-Aldrich, St Louis, USA) or Merck (Darmstadt, 
Germany). PCR was performed in a Biometra-Uno II termocycler (Biometra, Gõttingen, 
Germany). Sequencing reactions were prepared using the DNA Sequencing Kit 
BigDye™ Terminator Cycle sequencing Ready Reaction from Applied Biosystems and 
ran on the ABI PRISM™ 310 Genetic Analyser from Applied Biosystems (PE, Applied 
Biosystems, Foster City, CA). 
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Methods 
Biochemical studies 
Patients were biochemically diagnosed in the Enzymology Department of 
IGMJM, by ARSA activity determination in leucocytes and fibroblasts (Baum et al, 
1959; Lee-Vaupel and Conzelmann, 1987) and by the study of sulfatide excretion in 
urine (Berna et al, 1999). The activity of ARSA was also analysed in leukocytes and 
fibroblasts, after separation of the different arylsulfatases by an electrophoresis 
performed on sheets of cellulose acetate gels (Alves et al, 1986). 
Molecular Studies 
Genomic DNA was extracted from frozen leukocyte pellets, fibroblasts or buffy 
coats following standard methods. 
1. Screening, for frequent alterations 
Mutations IVS2+1G>A and P426L were tested by Allele Specific 
Oligonucleotide Hybridization (Polten et al, 1991) or by restriction analysis as 
indicated in Table 1. 
The ARSA-PD associated alterations, A3352G and N350S, were tested by Mae III 
restriction analysis and allele-specific PCR, respectively (Marcão et al, 2003a). 
2. Identification of other alterations 
Cases that remained with unknown mutations, after the initial screening for frequent 
alterations, were analysed by non-isotopic PCR-SSCA. The application of both 
horizontal (Amaral et al, 1996) and vertical (Ribeiro et al, 1996) SSCA analysis to 
nine fragments comprising all the ARSA exons (Table 1) resulted in the identification 
of 100% of the patients' alleles. Fragments presenting abnormal migration patterns were 
further examined by direct sequencing of asymmetric PCR generated products. In all 
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cases independent PCR samples were sequenced to confirm the reproducibility of the 
results. 
Table 1 - Amplification and analysis of different ARSA gene fragments 
ARSA gene PCR ann. 
fragmenta Oligonucleotide sequence b temp. (°C) Type of analysis 
ARSA571-898 5 ' AGCCTGCTGGAGCCAAGTA3 ' 
5'AGGAAAGGGATGGAGGGTC3' 
66 SSCA/ sequencing 
ARSA970-1332 5 TC AGGGACTCTGTGACTTGTC3 ' 
5 'TGAGGGCTGGGCTGGCAGGTG3 ' 
66 SSCA/ sequencing 
ARSA1023-1571 5'CGGTTCGGATGGGCATGTAC3' 66 Mva I restriction analysis 
5 'CGTGAGAGGCATAGTACAGGAAGAA3 ' for IVS2+1G>A detection. 
ARSA1322-1590 5'CCCAGCCCTCACGGCAGCT3' 
5 'GTTGGGCCAAGATCACTTA3 ' 
66 SSCA/ sequencing 
ARSA 1569-1891 5 ' ACGTAAGTGATCTTGGCCC3 ' 
5 'GCAAGCAGCTGAACTGCAA3 ' 
66 SSCA/ sequencing 
ARSA2081-2314 5 ' TC AG AGGCTGTGGCTCC AT3 ' 
5 'CAGTTCGCCATCAAGGTTG3 ' 
66 SSCA/ sequencing 
ARSA2298-2513 5'CCTTGATGGCGAACTGAG3 ' 
5 ' AGGACAGGGGCCAAGGAT3 ' 
66 SSCA/ sequencing 
ARSA2604-2887 5 'GGTTCCTGGGTGGGCAAGAAG3 ' 
5 ' AGGGATCTAGGGCTCCGGGGA3 ' 
66 SSCA/ sequencing 
ARSA2903-3212 5'CCTTGCCCTGTGCACAGAA3' 
5'GCAGCCAGGATGACAGCAGAT3' 
66 SSCA/ sequencing 
ARSA2981-3136 5 ' CTCCAGCTCTCTGACTGCTCATÇAG3 ' 65 Alw NI restriction analysis 
5 'GCGTCTAACTGGGCCTTGAGCAGC3 ' for P426L detection. 
ARSA3114-3417 5 'CTGCTCAAGGCCCAGTTAG3 ' 
5 ' ACC AGC AC AC AGC ATTACC3 ' 
66 SSCA/ sequencing 
PCR reactions (100 uL): IX PCR buffer, 1,5 mM MgCl2, 0.2 mM dNTPs, ImM primer #1, ImM primer 
#2, 200-800 ng of gDNA, 0.02 U/ uL of Taq DNA polymerase.a Genomic DNA nucleotide numbering is 
according to Kreysing et al. (1990).b Mismatch nucleotides are underlined. 
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3. Haplotvpe Studies 
W193C, gl923c, g2015a, T391S and c2842g polymorphisms were tested by 
endonuclease restriction digestion (Polten et al, 1991; Coulter-Mackie et al, 1997). 
Results 
Twelve of the sixteen non-related patients that were studied had mutation IVS2+1G>A, 
seven of them being homozygotes. Mutation P426L was only found in one juvenile 
patient, in heterozygosity with the missense mutation P425T (Table 2). None of the 
ARSA-PD associated alterations was found among the MLD patients. 
Six additional alterations were detected by SSCA/ sequencing (Table 2). Two of these 
mutations, I179S (Fluharty et al, 1991) and D255H (Lissens et al, 1996), were 
previously described in non-Portuguese patients. The other four alterations were found 
in Portuguese families: two microlesions that consisted of a C insertion and a C deletion 
in positions 412 and 1040 of cDNA (Stein et al, 1989), respectively, and two missense 
mutations that were a G899>T transversion causing substitution of Cys300 by Phe and a 
C1273>A transversion leading to the substitution of Pro425 by Thr (Marcão et al, 
1999). A summary of the results of the patients studied is presented in Table 2. 
The patients homozygous for mutation IVS2+1G>A were also homozygous for 
each of the five polymorphisms examined (Table 3), thus presenting the fixed haplotype 
reported by Zlotogora et al (1994). The results obtained for all the carriers of this 
mutation were also compatible with the existence of linkage disequilibrium with that 
same haplotype. Mutations cl040delC, D255H, I179S and c412insC were found in the 
context of different haplotypes as indicated in Table 3. In relation to mutations C300F, 
P426L and P425T (found in patients M and N, from whom no biological sample was 
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available at the time of the molecular characterisation), the associated haplotypes could 
only be partially determined by indirect study performed in the parents. 
77 
Table 2- Molecular and biochemical analysis of Portuguese patients with MLD 
> 1 
1 
e 
'•a 
cu 
MLD clinical 
form 
ARSA activity 
(nmol/h/mg) Sulfatide in urine Genotype 
1 A Late infantile 0 a Increased I / I 
2 B Late infantile 0 a Nd I / I 
C Late infantile 0 a Increased I / I 
3 D Late infantile 0 a Nd I / I 
4 E Late infantile 0 a Increased I / I 
5 F Late infantile 0 a Increased I / I 
6 G Late infantile 0a Increased I / I 
7 H Late infantile 0a Increased I / I 
8 I Late infantile 0a Increased cl040delC/cl040delC 
9 J Late infantile 0a Increased cl040delC/cl040delC 
10 K Late infantile 0a Nd I/c412insC 
11 L Late infantile 0a Increased I/D255H 
12 M* Late infantile 0a Nd C300F/C300F 
13 N* Juvenile 5b Nd P426L /P425T 
O Adult 0a Increased I/I179S 
14 P Adult 13" Increased I/I179S 
Q Adult 3 ? Increased I/I179S 
15 R Adult 0a Normal I/I179S 
S Adult 0a Normal I/I179S 
16 T Adult 0a Normal I/I179S 
Nd - Not determined. *Biological material from these patients was not available for the molecular studies, 
the study was done in the patients' parents DNA. "ARSA activity determined in leukocytes according to 
Lee-Vaupel M and Conzelmann E (1987), (reference values in the Enzymology Department (IGMJM): 6-
15 nmol/h/mg). bARSA activity determined in leukocytes according to Baum et al. (1959), (reference 
values in the Enzymology Department (IGMJM): 43-234 nmol/h/mg). Families 8, 10, 12, 13 and 14 were 
referred in previous publications (Alves et al, 1986; Marcão et al, 1999). 
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Table 3 - Haplotype analysis 
Polymorphisms 
Restriction 
endonuclease 
Bgll BsrI BamHI Nia III" Nia III' 
Mutations W193C T391S c2842g gl923c g2015a 
IVS2+1G>A C S g g g 
c412insC W T g a g 
I179S W T c a g 
D255H W S g g g 
C300F w S g ne g 
cl040delC w S g g g 
P425T w T ne ne g 
P426L w ne g g g 
ne - non conclusive. The results for mutations I179S, D255H and c412insC assume the haplotype Bgl I 
(C ), Bsr I (S), Bam HI (g), Nia III2 (g), Nia III1 (g) for allele Ivs2+1G>A. Nia III1 and Nia III2 
polymorphic sites denomination is according to Coulter-Mackie et al. (1997). 
Discussion 
The mutation profile of Portuguese MLD patients seems to be different from 
what has been described for other European populations (Figure 1). The most striking 
differences are the higher frequency of an ARSA null mutation (IVS2+1G>A), which 
represents 60% of the MLD alleles among unrelated Portuguese patients (67% among 
the late infantile patients) and the lower frequency of mutation P426L, which represents 
only 3% of those alleles. This latter mutation was not found among eighteen unrelated 
Spanish MLD patients and thus also seems to have a low frequency in Spain. 
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Nevertheless mutation IVS2+1G>A represents only 25% of the MLD alleles in the 
Spanish population (Gort et al., 1999). 
80 
Õ 60 
S 40 
20 
■ IVS2+10A 
D P426L 
Eh h m n i 
Polten, Eto, 1993 Barth, Draghia, Berger, Gort, 1999 This work 
1991 1993 1997 1997 
Figure 1. Frequency of mutations IVS2+1G>A and P426L in different European MLD 
populations. 
Zlotogora et al. (1994) identified this mutation in both Christian and Arab 
families from Jerusalem and, based on its linkage desequilibrium with a single rare 
haplotype, proposed that it could have had an European ancient origin, being introduced 
in Jerusalem at the time of the Crusades. The fact that this mutation was found in 
different regions of Portugal, in such a high frequency and in linkage desequilibrium 
with the same rare haplotype, might indicate that this is an ancient mutation in our 
population and that the Portuguese could even have had contributed to its spread among 
other populations. 
Haplotyping has also been done for the other mutant alleles and our results were 
in agreement with the fixed haplotypes previously proposed for mutations P426L, I179S 
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and D255H (Coulter-Mackie et al, 1997). In spite of the small number of unrelated 
cases reported, these results suggest the possible existence of common ancestors. 
As can be seen in Table 2, most late infantile patients (patients A to H) were 
homozygous for the null mutation IVS2+1G>A (Polten et al, 1991). Three other 
patients were found to be homozygous for mutations cl040delC (patients I and J) and 
C300F (patient M), and two patients were found to be compound hétérozygotes for 
mutation IVS2+1G>A and mutations c412insC (patient K) or D255H (patient L). 
Mutation D255H, a null mutation first described in two Belgian late infantile 
patients, also compound hétérozygotes with mutation IVS2+1G>A (Lissens et al, 
1996), seems to be relatively frequent in Spain where it represents 19% of the MLD 
alleles (Gort et al, 1999). However, among the Portuguese MLD patients it was found 
in only one allele. 
Mutation C300F was never found in a patient other than the one referred in 
Table 2. It originates an unstable, almost inactive enzyme with severe octamerization 
impairment in the lysosome (Marcão et al, 2003b; Marcão et al, 2003c). As expected 
from this severe biochemical phenotype, this mutation was found to be associated with 
the most severe clinical form of the disease (patient M). 
Mutation c412insC, found in exon 2 of patient K is also likely to be null, as it 
results in frameshift with altered sequence after amino acid 138, leading to the 
appearance of a stop codon 36 amino acids later. This mutation was recently reported in 
an heterozygous late infantile patient of Greek origin (Coulter-Mackie et al, 2003). 
Patients I and J were both homozygous for a microdeletion in exon 6 
(cl040delC). This deletion leads to the appearance of a stop codon in exon 8, predicting 
the truncation of the protein about 84 amino acids before its carboxy terminus. 
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Therefore, this is most certainly a null mutation, which is further supported by its 
identification in homozygosity in two late infantile patients. 
Mutation cl040delC was found to be associated to the same haplotype in the two 
families in which it was identified. This fact may suggest the existence of a common 
ancestor, but the occurrence of this mutation in a repetitive sequence of the arylsulfatase 
A gene and its association to an haplotype that is common among the general population 
does not allow the exclusion of the possibility of an independent occurrence in both 
families. 
The juvenile patient N was found to be a compound hétérozygote for missense 
mutations P425T and P426L. Both these mutations originate ARSA proteins with some 
residual enzyme activity but that are unstable in the lysosome (Polten et al, 1991; 
Marcão et al., 2003b). Interestingly, both these mutations were also found to affect the 
enzyme octamerization capacity, thus explaining its instability (von Bùlow et al, 2002; 
Marcão et al, 2003c). 
All the adult patients, belonging to three different families, presented the same 
genotype (IVS2+10A/ I179S). Mutation I179S seems to be the third most common 
mutation among European MLD patients, presenting a frequency of about 19% (von 
Figura et al, 2001). Even when in heterozygosity with null alleles, as is the case of the 
families here presented, this mutation has always been found associated with late-onset 
forms of MLD (von Figura et al, 2001). In a recent publication, Baumann et al (2002) 
reported its association with a more specific psycho-cognitive form of late onset MLD, 
characterized by initial behavioural disturbances and progressive mental deterioration. 
The same kind of phenotype was observed in the adult patients from families 14 and 16 
(we have no clinical information regarding patients from family 15). In spite of this 
82 
apparent clinical homogeneity, some variability was observed in terms of age of onset 
and rate of progression, even among the various affected siblings reported here. 
Biochemical variability was also observed among these three Portuguese families, as 
patients from families 15 and 16 do not excrete elevated amounts of sulfatides in urine. 
This lack of elevated amounts of sulfatide in urine seems to be rare, but was also 
reported for an Italian juvenile patient (Gomez-Lira et al, 1998) with the same 
genotype of the Portuguese patients (IVS2+1G>A/ I179S). The I179S mutation, which 
produces a mutant protein with some enzyme residual activity, but that is known to be 
particularly susceptible to proteolytic degradation (Fluharty et ah, 1991) may be in the 
origin of the variability encountered. In fact, juvenile and adult patients, with onset ages 
varying from 9 (Fluharty et al, 1991) to 62 years of age (Perusi et al, 1999), being 
compound hétérozygotes for the I179S mutation and null alleles or alleles with some 
residual enzyme activity, have been reported. No clear correlation seems to exist 
between the biochemical phenotype of the 2nd mutation and the clinical phenotype. This 
heterogeneity raises the question of the existence of additional factors interfering with 
the "in vivo" activity of ARSA, and thus with the clinical expression of MLD. 
In conclusion, a very high frequency of mutation IVS2+1G>A was found among 
the Portuguese MLD patients. Haplotype analysis corroborated the hypothesis that this 
mutation may have its origin in a common European ancestor. The molecular 
heterogeneity reported to be present in MLD patients is illustrated by the finding of 
eight different mutations among this group of sixteen non-related patients, three of 
which were never reported in non-Portuguese patients. Nevertheless, seven of the 
twelve late infantile patients were homozygous for mutation IVS2+1G>A and all adult 
patients have the same genotype (IVS2+1G>A/ I179S). Our results also confirm the 
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existence of a general genotype-phenotype correlation in MLD: late infantile patients 
have two null alleles, while the presence of at least one allele coding one enzyme with 
some residual activity mitigates the course of the disease originating a late onset form. 
However, some biochemical and clinical variability have been found among late onset 
patients. This is quite obvious from the comparison of the three adult families (all 
presenting the same genotype) and could be found even within each family. Given the 
fact that in the less severe forms of the disease the life expectancy of the patients is 
much longer, it seems likely that the effect of other environmental or genetic factors 
might become more evident, leading to a wide clinical heterogeneity, inter and 
intrafamilial, associated to the same arylsulfatase A genotype. 
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Abstract 
Arylsulfatase A pseudodeficiency (ARSA-PD) may be related to increased susceptibility to neuro-psychiatric disorders. An 
association of allele 2417G/3352A with schizophrenia was found in a group of Portuguese patients. In the Portuguese population, at 
least one PD associated alteration exists in 18.3% of the ARSA alleles. Allele 2417G/3352G was invariably associated with a 
conserved haplotype, while 2417G/3352A and the rare 2417A/3352G alleles appeared on different haplotypes. 
© 2003 Published by Elsevier Science (USA). 
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Introduction 
Metachromatic leukodystrophy (MLD) is an auto-
somal recessive disorder characterized by a severe cen-
tral and peripheral nervous system involvement, and 
usually due to the deficiency in the lysosomal enzyme 
arylsulfatase A (ARSA, EC 3.1.6.8) [1]. Arylsulfatase A-
pseudodeficiency (ARSA-PD), is a relatively frequent 
condition among the general population, which is 
characterized by a reduction to 5-15% of ARSA normal 
activity, and occurs in individuals who have no MLD 
and no sulfatide accumulation in tissues or excretion in 
urine [1]. The molecular defects in the origin of ARSA-
PD consist of two A-»G transitions in the ARSA 
coding gene (nucleotides 2417 and 3352 according to the 
GeneBank sequence X52150), that can be found isolated 
or combined, the first altering a N-glycosylation site and 
the second altering a polyadenylation signal [21 
The association between ARSA-PD and different 
neuro-psychiatric symptoms has been suggested by dif-
ferent authors (see [1] for review). In order to investigate 
'Corresponding author. Fax: +351-22-6052404. 
E-mail address: mcsamir@ibmc.up.pt (M.C. Si Minada). 
the possible association of low ARSA activity and 
schizophrenia, we determined the frequency of ARSA-
PD alleles in the Portuguese population and in a group 
of Portuguese patients suffering from schizophrenia. 
The existence of several polymorphic sites within the 
ARSA gene, present in linkage disequilibrium in ARSA-
PD alleles, has long been known [3]. The determination 
of ARSA-PD allele frequencies and haplotype analysis 
in different populations has raised several hypotheses 
regarding the order of appearance of the alterations that 
characterise the ARSA-PD alleles and its appearance as 
a single or a recurrent event [4]. Haplotype analysis of 
ARSA-PD and normal alleles, regarding six intragenic 
polymorphisms, was also carried out in this work. 
Materials and methods 
Patients and control samples 
ARSA-PD associated alterations were studied in 161 
healthy Portuguese blood donors (age 5» 18 years) and 
33 Portuguese patients suffering from schizophrenia, 
according to the DSM-IV diagnostic criteria, and with a 
1096-7192/$ - see front matter O 2003 Published by Elsevier Science (USA). 
doi:l0.1016VS1096-7192<03)00092-l 
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mean age of 47 years. Additionally, 23 individuals non-
carriers of the ARSA-PD associated alterations, 10 
individuals homozygous for allele 2417G/3352G, 12 in-
dividuals homozygous for allele 2417G/3352A and one 
hétérozygote for both alleles, were used for the haplo-
type analysis. All blood samples were taken after in-
formed consent was granted. Genomic DNA was 
isolated following standard methods. 
Material 
Oligonucleotides were provided by Amersham Phar-
macia Biotech (Freiburg, Germany). Restriction endo-
nucleases were from New England Biolabs (Frankfurt 
am Main, Germany) or Roche Applied Science 
(Mannheim, Germany). Taq DNA polymerase was from 
Invitrogen (Groningen, The Netherlands). Other re-
agents were from BioWhittaker Molecular Applications 
(BMA, Rockland, USA), Invitrogen (Groningen, The 
Netherlands) or Applied Biosystems (PE, Applied Bio-
systems, Foster City, CA). 
Methods 
The alterations associated with ARSA-PD (A2417G, 
A3352G), were tested as indicated in Table 1. To per-
form the haplotype analysis, four fragments, comprising 
the gene regions of six polymorphisms described in the 
ARSA codifying gene (G1471T, G1923C, A2015G, 
C2790G, C2842G, G3220A, nucleotide numbering ac-
cording with GeneBank sequence X52150), were am-
plified by PCR and tested by restriction endonuclease 
analysis (Table I). 
Results and discussion 
In the Portuguese control population, the two most 
frequent ARSA-PD alleles have approximately the same 
frequency (9.3 and 8.7%, respectively for alleles 2417G/ 
3352G and 2417G/3352A), whereas the rare allele 
2417A/3352G was found in only one individual, in 
heterozygosity with the allele 2417G/3352G. Taking the 
frequencies of the three alleles together, we have the 
highest value reported in a population of European or-
igin (18.3%), which indicates the importance of ARSA-
PD in the Portuguese population. 
Seventeen different haplotypes were identified among 
the individuals for whom haplotype analysis was carried 
out. Looking at the percentage of each polymorphism in 
the control population we found BgR (G) in 97.8% of 
the alleles, Bsrl (G) in 61%, BamHI (G) in 85%, 
MflIII2(G) in 84.8%, Malll1 (G) in 93.5%, and Acil (G) 
in 97.8% of the alleles. 
The doubly mutated alleles 2417G/3352G were found 
to have exclusively one of the rare haplotypes: BgR (T) 
Bsrl (C) BamEl (G) JVMII2 (G) Malll1 (G) Acil (G), 
which was found in 8.6% of the normal alleles and in 
none of the 2417G/3352A alleles. These results confirm 
the association of the doubly mutated ARSA-PD allele 
with a highly conserved haplotype [3], which together 
with its high frequency in Europeans and its absence in 
Table 1 
Detection of alterations in the ARSA gene by restriction endonuclease analysis and allele specific PCR 
Polymorphism Reference ARSA gene 
fragment 
Oligonucleotide sequences PCR arm. Detection 
temp. method 
66 BgR 
58 Nlallï 
58 Nlam 
66 Bsrï 
66 BamUl 
66 Acil 
66 MaeVX 
58 Specific PCR 
58 Specific PCR 
G1471T Polten et al., ARSA1322/ 
(W193C) N. Engl. J. Med., 1991 ARSA1590 
G1923C Coulter-Mackie et al., ARSA1569/ 
(intron 4) Am. J. Med. Genet., 1997 ARSA2058 
A2015G Coulter-Mackie et al., ARSA1569/ 
(intron 4) Am. J. Med. Genet., 1997 ARSA2058 
C2790G Polten et al.. ARSA2604/ 
(T39IS) N. Engl. J. Med., 1991 ARSA2887 
C2842G Polten et al., ARSA2604/ 
(intron 7) N. Engl. J. Med., 1991 ARSA2887 
G3220A Ricketts et al., ARSA3114/ 
(R496H) Hum. Mutât-, 1998 ARSA3417 
A3352G Gieselmann et al., ARSA3114/ 
(polyA) Proc. Natl. Acad. Sei., 1989 ARSA3417 
A2417G Gieselmann et al., ARSA2298/ 
(N350S) Proc. Natl. Acad. Sei., 1989 ARSA2434 
ARSA2298/ 
ARSA2434 
5'CCCAGCCCTCACGGCAGCT3' 
5'GTTGGGCCAAGATCACTTA3' 
5'ACGTAAGTGATCTTGGCCC3' 
5'CCCACACCTCTAAGTCACA3' 
5'ACGTAAGTGATCTTGGCCC3' 
5'CCCACACCTCTAAGTCACA3' 
5'GGTTCCTGGGTGGGCAAGAAG3' 
5'AGGGATCTAGGGCTCCGGGGA3' 
5'GGTTCCTGGGTGGGCAAGAAG3' 
5'AGGGATCTAGGGCTCCGGGGA3' 
5'CTGCTCAAGGCCCAGTTAG3' 
yACCAGCACACAGCATTACCy 
5'CTGCTCAAGGCCCAGTTAG3' 
5'ACCAGCACACAGCATTACC3' 
yCCTTGATGGCGAACTGAG3' 
5'AGCCATCCAAGGTGACAC3' 
5'CCTrGATGGCGAACTGAG3' 
S'AGCCATCCAAGGTGACAXy 
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non-Europeans [4], strongly suggests a single ancient 
origin posterior to the divergence of European and 
Asian populations. The identification of the singly mu-
tated alleles on different haplotypes may suggest the 
existence of de novo mutation events. Allele 2417G/ 
3352A appeared on six different haplotypes, although 
half of the alleles have the same haplotype (BgK (T) Bsrl 
(G) BarriHI (G) MalU2 (G) NlalTL1 (G) Acil (A)), which 
was absent from the control alleles. Analysis of the 
hétérozygote individual with alleles 2417G/3352G and 
2417A/3352G revealed an haplotype {BgR (G, G) Bsrl 
(C, Q Bamm (C, C) iVMII2 (G, G) iWalll1 (G, G) Acil 
(G, G)) that is different from the one previously reported 
for another similar singly mutated allele [5]. The existing 
data does not allow us to exclude the possible existence 
of de novo mutations on different haplotype back-
grounds nor the possible divergence of the polymorphic 
backgrounds of the mutated alleles. 
The possible association between ARSA-PD and 
different neuro-psychiatric conditions has been investi-
gated for many years, but with the exception of two 
alcoholism-related studies [6,7], in which a link is es-
tablished between this condition and the ARSA-PD al-
lele 2417G/3352A, all the other studies were done only 
by biochemical determination of ARSA activity "in vi-
tro" and led to inconclusive results. In this study, the 
possible association between ARSA-PD and schizo-
phrenia was investigated by comparing the frequency of 
the ARSA-PD associated alleles in the healthy Portu-
guese population and in a group of Portuguese patients 
with the diagnosis of schizophrenia. Among these pa-
tients we found frequencies of 3% for allele 2417G/ 
3352G and 21.2% for allele 2417G/3352A. Although 
these two alleles were in Hardy-Weinberg equilibrium in 
both the control and the schizophrenic population 
samples, allele 2417G/3352A has a statistically signifi-
cant higher frequency in the latter group (x2 test, 
p < 0.05), which supports the idea of an increased risk 
for 2417G/3352A allele carriers to develop schizophre-
nia. This same allele has previously been reported as 
having a higher frequency among alcoholic patients 
[6,7]. 
Therefore, in addition to the diagnosis problems re-
sulting from the low ARSA activity not associated with 
MLD clinical symptoms, there is also the possibility of 
ARSA-PD contributing to the susceptibility of devel-
opment of neuro-psychiatric conditions. Moreover, it 
has been suggested that a reduced activity of ARSA, in 
the presence of detrimental stimuli such as lead [8] or 
alcohol [9], could lead to accumulation of sulfatide in 
cells of the nervous system resulting in impaired func-
tion. Thus, it seems that ARSA-PD may have important 
clinical implications, justifying the studies on this sub-
ject, which we are pursuing. 
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Biochemical Characterization of Two (C300F, P425T) 
Arylsulfatase A Missense Mutations _ _ _ 
Ana Marcão,1 Heidi Simonis,2 Frank Schestag,2 M. Clara Sá Miranda,1 and Volkmar Gieselmann2* 
instituto de Biologia Molecular e Celular, University of Porto, Porto, Portugal 
HnsTut^rpXysiologische Chemie, Rheinische Friedrich Wilhelms Universitat, Bonn, Germany 
Metachromatic leukodystrophy (OMIM 
250100) is a lysosomal storage disease caused 
by the deficiency of arylsulfatase A (ARSA, 
EC 3.1.6.8). This disease affects mainly the 
nervous system, because patients cannot 
degrade 3-O-sulfo-galactosylceramide (sulfa-
tide), a major myelin lipid. Here we describe 
the characterization of the biochemical 
effects of two arylsulfatase A missense muta-
tions, P425T and C300F. Transfection ex-
periments demonstrate the expression of 
residual ARSA enzyme activity for P425T, 
but not for C300F substituted ARSA. Relative 
specific activity determination showed that 
the P425T substituted enzyme has retained 
about 12% of specific enzyme activity, 
whereas the C300F substituted enzyme is 
reduced to less than 1%. Pulse-chase experi-
ments reveal that both mutant proteins are 
unstable, with a half life of less than 6 hr. 
Increased secretion upon addition of NH4C1 
indicates that the mutant proteins can pass 
the Golgi apparatus and thus are not de-
graded in the endoplasmic reticulum (ER), 
but in the lysosomes. This is supported by 
experiments, which demonstrate the pre-
sence of mannose-6-phosphate residues on 
the oligosaccharide side chains of the mutant 
proteins. Addition of the cysteine protease 
inhibitor leupeptin increases the amount of 
ARSA activity in cells expressing the P425T 
substituted enzyme, whereas no increase in 
activity was seen with C300F substituted 
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INTRODUCTION 
Arylsulfatase A is the lysosomal enzyme that cata-
lyzes the first step in the degradation of sulfatide 
(3-O-sulfogalactosylceramide), one of the major sphin-
golipids in myelin. Deficiency of this enzyme causes 
metachromatic leukodystrophy, a disease that is charac-
terized hy sulfatide accumulation in different tissues. 
Oligodendrocytes and Schwann cells are the most 
affected. Thus, patients develop a progressive demyeh-
nation and a wide variety of neurological symptoms, 
metachromatic leukodystrophy (MLD) is clinically 
heterogeneous, presenting with three different forms 
classified according to the age of onset: late infantile, 
juvenile, and adult forms [for review see Von Figura 
et al., 2001]. 
The ARSA locus is located on chromosome 22qld; the 
gene is divided into eight exons encompassing 3.2 Kb 
(GenBankX52150). It codes for an enzyme of 507 ammo 
acids [Stein et al., 1989; Kreysing et al., 1990]. A large 
number of mutations has been reported m the ARSA 
gene. Most are private and only a small number of 
them were biochemically characterized [Von Figura 
et al., 2001]. . 
A genotype-phenotype correlation exists m MLD: 
patients homozygous for alleles associated with no 
residual activity usually present the late infantile form 
of the disease, while patients with at least one allele or 
two alleles coding for an enzyme with some residual 
activity present less severe, juvenile or adult forms. 
This correlation was first suggested by Polten [Polten 
etal., 1991] and has been supported by biochemical data 
from several reports [Bohne et al., 1991; Fluharty et al., 
1991; Leinekugel et al., 1992; Kappler et al., 1994; 
Hess et al., 1996; Coulter-Mackie et al., 1997; Hermann 
et al., 2000]. 
In this article, two defective ARSA proteins are 
biochemically characterized. Activity, stability, and 
sorting of these enzymes are analyzed and the obtained 
data are discussed according to the clinical phenotype of 
the patients. 
© 2002 Wiley-Liss, Inc. 
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MATERIALS AND METHODS 
Patients 
The mutations characterized in this study were found 
in two Portuguese patients. One of these patients 
presented the late infantile clinical form of MLD and 
was homozygous for the alteration that changes cysteine 
300 into phenylalanine. The other patient presented the 
juvenile form of the disease and was a compound 
hétérozygote for mutation P426L [Polten et al., 1991] 
and a mutation that changes proline 425 into threonine. 
Both of these patients were previously reported [Marcão 
et al., 1999]. 
Material 
Taq polymerase, LIPOFECT AMINE Reagent, G418, 
and cell culture media were from Life Technologies 
(Eggenstein, Germany). Oligonucleotides were pur-
chased from MWG-Biotech (Ehersberg, Germany). 
Restriction enzymes and DNA modifying enzymes were 
from New England Biolabs (Frankfurt am Main, 
Germany) or Life Technologies. Endoglycosidase H 
was from Roche. [36S]-methionine (specific activity 
>600Ci/mmol) and [32P]-orthophosphate (specific activ-
ity >3,000 Ci/mmol) were from Amersham Phar-
macia (Freiburg, Germany). PANSORBIN was from 
Calbiochem-Novabiochem (Schwalbach, Germany). 
Other reagents were from Sigma or Merck. 
In Vitro Mutagenesis 
Mutations C300F and P425T were introduced into the 
pAlter mutagenesis vector from Promega according to 
the protocol supplied by the manufacturer. The insert of 
the vector contained an SV40 early promoter, the ARSA 
cDNA and a polyadenylation sequence from the pBEH 
ARSA vector described previously [Artelt et al., 1988; 
Stein et al., 1989]. The oligonucleotides that were used 
to introduce mutations have the following sequences: 
C300F-5'TGCTCCGGACTCTTGCGGTTTGGAAAGGG-
A3' and P425T-5'ACTGCTCATGAGACCCCGCTCC-
TCTATGAC3'. The introduction of these mutations 
was confirmed by DNA sequencing. 
Activity, Stability and Intracellular 
Localization of Mutant ARSAs 
BHK-21 cells were transiently transfected with the 
mutagenesis vector using lipofectamine, as described 
[Hermann et al., 2000]. After 48 hr, the cells were 
harvested and ARSA activity was measured in cellular 
extracts using the artificial substrate p-nitrocatechol-
sulphate. Total protein determination and Western blot 
analysis were also done. 
The mutated ARSA cDNAs were subcloned into the 
expression vector pBEH [Artelt et al., 1988]. A neomycin 
cassette, containing a neomycin resistance gene with an 
SV40 promoter and a polyadenylation signal was insert-
ed at the unique Aat II restriction site. To generate 
stably transfected cell lines, Ltk cells were transfected, 
using lipofectamine, and selected for two weeks with 
lmg/ml G418. After this time, metabolic labeling, 
immunoprecipitation, and digestion of ARSA with 
endoglycosidase H were done, as described before 
[Gieselmann et al., 1992], with minor modifications. 
An ARSA anti-serum, raised against recombinant ARSA 
in rabbits, was used. 
RESULTS 
ARSA Activity in Transiently Transfected 
BHK-21 CeUs 
The mutations causing the P425T and C300F amino 
acid substitutions have recently been described, but 
their deleterious effect on ARSA activity expression has 
not been confirmed. To verify that the mutations are 
pathologic, amino acid substitutions P425T and C300F 
were introduced into the normal ARSA cDNA by in vitro 
mutagenesis. The mutated cDNAs were transiently 
expressed in BHK-21 cells. 
Five independent transient transfections were done 
for each mutation. 
Figure 1 shows that enzyme activity expression is 
severely reduced for mutant P425T and completely 
absent for mutant C300F. To investigate ARSA relative 
specific activities (Table I), we determined the enzyme 
activity and the amount of ARSA cross-reacting mate-
rial via Western blot analysis in the same cell lysates. 
The results reveal that the P425T substituted protein 
has considerable residual specific activity of about 12% 
of normal, whereas the specific activity of the C300F 
substituted ARSA is less than 1%. 
It has previously been demonstrated that some 
mutant ARSA proteins can be stabilized in cultured 
cells by the addition of the protease inhibitor leupeptin 
[Von Figura et al., 1983]. Upon addition of leupeptin the 
ARSA activity in transiently transfected 
BHK-21 cells 
Fig. 1. ARSA activity in transiently transfected BHK-21 cells. ARSA 
activity was calculated as the average of five independent transfection 
experiments and is expressed as mU ARSA/mg total protein. Bars indicate 
standard deviation. To determine endogenous activity of BHK-21 cells, the 
same vector, but with an insert encoding a nonrelated protein, was also 
transfected and ARSA activity was measured. The bottom shows the result 
of a Western blot analysis of cell homogenates of transfected cells confirming 
the presence of ARSA cross-reacting material. 
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TABLE I. ARSA Relative Specific Activity* 
WT P425T C300F BHK-21 
301.5 
2,427 
100% 
39 
2,654 
12% 
3 
4,216 
0.6% 
ARSA activity-ARSA endogenous activity (uU) 
Western blot arbitrary units 
Relative specific activity — — — — — 
"To estimate the relative specific activities of the mutant enzymes, transiently transfected BHK-21 cells were 
a n L y f e T f o r ^ 
ïïSïS laser scan densitometry of the X-ray mms and are presented m arb.traryumts.Relat.ve 
sp^mdtóvity was calculated as the quotient between AKSA activty and the Western blot signal 
ARSA activity in the cells increases and the catahohsm 
of sulfatide is normalized. To investigate whether the 
P425T and C300F substituted enzymes can also be 
stabilized by cysteine protease inhibitors, leupeptin was 
added to transiently transfected cells and enzyme 
activity was determined. Table II shows that addition 
of leupeptin leads to a considerable increase of enzyme 
activity in the cells expressing the P425T substituted 
enzyme. However, the protease inhibitor has no influ-
ence on ARSA activity in cells expressing the C300F 
substituted ARSA. 
Stability and Intracellular Localization of the 
Mutant ARSA Polypeptides 
To investigate the effects of the amino acid substitu-
tions on the stability of the mutant proteins, pulse chase 
experiments were performed. 
Stably transfected Ltk" cells expressing wild-type 
ARSA C300F, andP425T substituted ARSA were pulse-
labeled for 3 hr with [35S]-methionine and chased up to 
72 hr. , A , . 
Figure 2 shows that the wild-type enzyme is stable 
during the entire chase period, whereas both mutant 
enzymes are rapidly degraded. More than half of the 
mutated proteins are already degraded after 6-hr chase, 
an almost complete degradation occurring after 24 hr. 
Premature degradation of mutant ARSA can either 
occur in the endoplasmic reticulum (ER) or in the 
lysosomes. To investigate whether the mutated proteins 
can leave the ER, pulse-chase experiments in the 
presence of NH4C1 were done. NH4C1 interferes with 
the cellular sorting of newly synthesized lysosomal 
TABLE II. Effect of Leupeptin in the ARSA Activity of 
Transiently Transfected BHK-21 Cells  
enzymes in a post Golgi compartment, targeting them 
improperly to the secretory pathway. If upon addition of 
NH4C1 mutant proteins can be found in the media of 
cultured cells, this indicates that these enzymes must 
have passed the Golgi apparatus and thus are able to 
leave the ER [Chang et al., 1988]. Cells were pulse 
labeled with [35S]-methionine and chased in the absence 
or presence of NH4C1. ARSA was immunoprecipitated 
from cells and media. The amount of C300F and P425T 
substituted ARSA secreted into the medium increases in 
the presence of ammonium chloride (Fig. 3) which 
indicates that the mutant proteins are not arrested in 
the ER. 
The synthesis of the mannose 6-phosphate residues on 
the oligosaccharide side chains of lysosomal enzymes 
occurs in the Golgi apparatus. Thus, demonstration of 
the presence of phosphate residues on N-linked oligo-
saccharide side chains is another proof for Golgi passage 
of a lysosomal enzyme. Ltk cells expressing the 
mutated proteins and the wild-type ARSA were pulse-
labeled for 5 hr with [32P]-orthophosphate. After 
immunoprecipitation the proteins were digested with 
endoglycosaminidase H, which removes high mannose-
type oligosaccharide side chains. 
Figure 4 shows that both mutant enzymes are labeled 
by [ P]. The radioactive label can be removed by EndoH 
digestion, indicating its presence on high mannose type 
N-linked oligosaccharide side chains. 
DISCUSSION 
We biochemically characterized two missense muta-
tions in the ARSA gene. The mutations have been 
Chase (h) 
6 24 48 72 
ARSA activity (mU/mg protein 
Leupeptin (100 uM) 
Expressed protein 
LAP 
ARSA-C300F 
ARSA-P425T 
ARSA-WT 
11.40 
7.77 
11.89 
47.55 
+ 
8.90 
10.64 
45.85 
46.35 
LAP, lysosomal acid phosphatase. BHK-21 cells were transiently trans-
fected to express the wild-type or substituted AHSA indicated m the table 
Control cells were transfected with a plasmid coding for lysosomal acid 
phosphatase (LAP) Leupeptin (100 uM) was added after the transection. 
The cells were harvested and ARSA activity and protein were measured in 
cell homogenates, 48 hr, after transfection. 
WTARSA 
C300F 
P425T 
Fie 2 Stability of wild-type and mutated ARSA polypeptides. Stable 
transfected Uk" cells expressing wild-type or C300F and P425T substituted 
ARSA were metabolically labeled for 3 hr with [36S]-methiomne and chased 
for the times indicated. ARSA was immunoprecipitated from the cell lysates 
and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
and fiuorography. 
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ARSA sorting 
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Fig 3 Effect of NH4C1 on sorting of wild­type and mutant ARSA polypeptides. Ltk" cells stably expressing the wild­type or the mutant 
proteins were pulse­labeled for 2 hr with [35S]­methionine and chased for 12 
hr in the presence or in the absence of 10 mM NH4C1. After immunopre­cipitation of ARSA from the medium and the cells, ARSA was analyzed by 
sodium dodecyl sulfate­polyacrylamide gel electrophoresis and nuorogra­
phy The bars indicate the percentage of ARSA cross­reactmgmatenal found 
in the cells (C) or in the media (M) and show the average of two independent 
experiments. 1, no chase; 2, 12­hr chase; 3­12­hr chase in the presence of 
NH4CI. For each protein, 100% ARSA = CI + Ml. 
reported previously but their biochemical consequences 
have not been examined so far. Here we show that about 
10% residual enzyme activity can be expressed from the 
P425T allele but not from the C300F allele. This is m 
accordance with the finding that the P425T ARSA has 
considerable residual specific enzyme activity, whereas 
that of the C300F is at the limit of detection (Fig. 1, 
Table I). 
Biosynthesis studies show that both mutant enzymes 
are more rapidly degraded than the wild­type ARSA. 
The latter is stable over a chase period of 72 hr, whereas 
the mutant enzymes are partially and completely de­
graded after 6 hr and 24 hr of chase, respectively (Fig. 2). 
Decreased stability of mutant ARSA frequently con­
tributes to the enzyme deficiency in MLD [Kafert et al., 
1995; Hess et al., 1996]. Previous studies have shown 
that the degradation of the mutant enzymes occurs 
either in the ER [Kafert et al., 1995; Hess et al., 1996] or 
in the lysosomes [Von Figura et al., 1983; Kreysing et al., 
1993]. This means that the structural alterations 
resulting from mutations in this protein, lead either 
to endoplasmic reticulum retention and degradation 
EhdoH 
ARSA-+ 
Fig 4 Phosphorylation of mutated ARSA polypeptides. Ltk cells, 
expressing wild­type or substituted ARSA polypeptides, were metabohcally 
labeled for 5 hr with [32P]­orthophosphate. ARSA was immunoprecipitated 
from the cell lysates and digested with endoglycosidase H before sulfate­
polyacrylamide gel electrophoresis analysis. 
[Kafert et al., 1995; Hess et a l , 1996] or cause an in­
creased sensitivity for lysosomal proteases [Von Figura 
et al., 1983; Kreysing et al., 1993]. Here we demonstrate 
an increased secretion upon addition of NH4C1 of both mutant enzymes (Fig. 3). Since this drug interferes with 
lysosomal enzyme sorting in a post Golgi compartment, 
this suggests that these enzymes are not arrested m 
the ER. This is supported by the presence of mannose 
6­phosphate residues on the oligosaccharide side chains 
of the mutant enzymes (Fig. 4), because these residues 
are generated in a post ER compartment. 
The biochemical properties of the P425T mutation 
resemble those of a previously described amino acid 
substitution, which occurs in the neighboring amino 
acid, P426L. The latter is one of the most frequent 
mutations found among whites [Polten et al., 1991]. The 
P426L substituted enzyme is correctly synthesized and 
sorted, but is rapidly degraded in the lysosomes. This 
degradation could also be partially blocked by leupeptin 
[Von Figura et al., 1983]. At neutral pH ARSA is a dimer 
that octamerizes in a pH dependent manner in the acidic 
environment of the lysosome. Octamerization of the 
P426L substituted enzyme is impaired and this allows 
cathepsin L to cleave the mutant enzyme [von Bulow, 
2002]. It seems likely that the P425T substitution 
described here, may also interfere with octamerization 
explaining its cysteine protease sensitivity. Thus, this 
mutation has biochemical properties, which are similar 
to those of the P425T mutation described here. Prolines 
425 and 426 are part of a PPLL motive that is strongly 
conserved among different sulfatases [Von Figura et al., 
2001]. Thus, it seems that independent of the mutations, 
alterations of this motif have similar consequences, 
namely, increased intralysosomal susceptibility for 
cysteine proteinases. 
The biochemical data presented here fit well into the 
established genotype­phenotype correlation of MLD. 
The juvenile patient carrying the frequent P426L 
mutation in one allele was found to be a compound 
hétérozygote for P425T mutation in ARSA's exon 8. Both 
mutations still allow for the expression of low residual 
enzyme activities and thus, explain the late­onset 
phenotype of the patient. 
The C300F allele was found in homozygosity in a 
patient with the severe late infantile form of the disease. 
We have shown that no enzyme activity can be expressed 
from the allele carrying this mutation. This enzyme is 
also sorted correctly to the lysosomes and thus resem­
bles the P425T ARSA. Since it also displays a compar­
able stability in pulse­chase experiments, the main 
reason for the difference in enzyme activity must be the 
reduced specific activity of the enzyme. Therefore, the 
addition of leupeptin cannot increase the ARSA activity 
in cells expressing this mutant, because in contrast to 
the P425T substituted enzyme, C300F is enzymatically 
inactive (Fig. 1, Table I). 
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2A.2. BIOCHEMICAL CHARACTERIZATION OF A NEW 
ARSA GENE MUTATION ASSOCIATED WITH AN 
ADULT ATYPICAL MLD CLINICAL PHENOTYPE 
ADULT ONSET MLD WITHOUT PERIPHERAL NERVOUS SYSTEM INVOLVEMENT: A CASE 
WITH A NEW MUTATION IN THE ARSA GENE 
Marcão A, Wiest R, Schindler K, Wiesmann U, Schroth G, Sá Miranda MC, 
Sturzenegger M, Gieselmann V 
Abstract 
We report the case of a 37-year old woman of tamile origin who presented with rapidly 
progressive dementia and behavioural abnormalities due to adult onset Metachromatic 
Leucodystrophy (MLD), a disease that usually affects the central and peripheral nervous 
system. As expected, MRI of the patient showed severe subcortical brain atrophy and 
extended T2 hyperintense signal alterations of white matter. Surprisingly, the cerebellar 
white matter was not affected and the patient did not show any clinical, 
neurophysiological or pathological signs of peripheral nervous system dysfunction. In 
accordance with these findings the patient did not present with ataxia or symptoms of 
peripheral neuropathy, which are frequent in MLD. Genetic analysis revealed 
homozygosity for a novel mutation in exon 3 of the arylsulfatase A gene (F219V). This 
substitution leads to a misfolded, unstable enzyme with a specific activity of less than 
1% of normal. This results in a severe enzyme deficiency, which is unusual in adult 
patients. 
Introduction 
Metachromatic Leukodystrophy (MLD; OMIM 250100) is an inherited 
lysosomal storage disorder caused by the deficiency of the Arylsulfatase A (ARSA; E.C. 
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3.1.6.8). ARSA catalyses the first step in the intralysosomal degradation of 3-O-sulfo-
galactosylceramide (sulfatide), namely the desulfation of the galactose moiety of this 
sphingolipid. Sulfatide is found in various tissues like the distal tubules of the kidney, 
bile duct epithelia and in particularly high concentrations in myelin of the nervous 
system. ARSA deficiency causes intralysosomal accumulation of sulfatide, which 
affects the oligodendrocytes and Schwann cells leading to progressive demyelination in 
the central and peripheral nervous system, respectively (for review see 1). 
Three forms of MLD, according to the age of onset, can be distinguished: a late 
infantile form with onset at the age of 1-2 years and early death of the individual; a 
juvenile form starting at the age of 3 to 16 years; and an adult form (onset >16 years) 
with a more protracted course1. A genotype-phenotype correlation has been described 
for MLD: patients who are homozygous for alleles which do not allow for the 
expression of any residual enzyme activity suffer from the most severe, late infantile 
form of the disease, whereas homozygosity for alleles allowing for the expression of 
residual enzyme activity in many cases causes the mild adult forms of the disease. 
Patients heterozygous for these two kinds of alleles frequently suffer from the 
intermediate juvenile MLD ' . 
Up to now, more than 90 different mutations causing the disease have been 
described in the ARSA gene (1 and www.hgmd.org). Only few of these alleles are 
frequent among patients, whereas most mutations are unique to individual families1. 
Here we present an unusual case of adult MLD caused by a novel mutation in the 
exon 3 of the arylsulfatase A gene (F219V). 
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Patient and Methods 
Case report 
A 37-year-old woman, whose parents were related and of tamile origin, 
presented with inadequate and bizarre behaviour after birth of her third child in 1997. 
She had been working as a housewife since her emigration to Switzerland in 1989 and 
was described as well organised and intelligent. She had been trained as a primary 
school teacher in Sri Lanka and worked without problems as a teacher until 1989. In 
1997 she showed progressive apathy, loss of interest in daily living routines and care of 
her three children. Memory functions deteriorated dramatically and she developed 
bladder incontinence. In May 1997 she was referred to the hospital because of a fall that 
originated a head injury. At that time, CT scans showed moderate ventricular 
enlargement, extended and marked white matter lesions. Further evaluation revealed 
severely impaired cognitive and mental functions, but there were no signs of peripheral 
nervous system involvement, a sural nerve biopsie as well as the electrophysiological 
studies revealed normal. MRI studies showed severe subcortical brain atrophy and 
extended T2 hyperintense signal alterations, nevertheless the cerebellar white matter 
was not affected. 
Materials 
Taq polymerase, LIPOFECTAMINE™ Reagent, G418 and cell culture media were 
from Life Technologies (Eggenstein, Germany). Oligonucleotides were purchased from 
MWG-Biotech (Ebersberg, Germany). Restriction enzymes and DNA modifying 
enzymes were from New England Biolabs (Frankfurt am Main, Germany) or Life 
Technologies. [35S]-methionine (specific activity > 39 TBq/mmol) was from Amersham 
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Pharmacia (Freiburg, Germany). PANSORBIN was from Calbiochem-Novabiochem 
(Schwalbach, Germany). Other reagents were from Sigma (Deisenhofen, Germany) or 
Merck (Darmstadt, Germany). 
DNA sequence analysis 
The ARSA gene of the patient was amplified in two overlapping fragments and 
sequenced completely. Amplification, sequencing strategy and sequences of primers 
used for amplification and sequencing have been described in detail . 
"In vitro" mutagenesis 
Mutation F219V was introduced into the ARSA cDNA5 by site directed 
mutagenesis. For that purpose a fragment from the vector pBEH-ARSA containing the 
SV40 early promoter, the ARSA cDNA and a polyadenylation sequence5'6 was cloned 
in the pALTER mutagenesis vector from Promega. "In vitro" mutagenesis was 
performed according to the protocol supplied by the manufacturer. The oligonucleotide 
that was used for the introduction of the F219V mutation had the sequence: 5'-
GATCGCCCCGTCTTCCTGTAC-3'. The introduction of this mutation was confirmed 
by DNA sequencing. 
Transfections, metabolic labelling and immunoprecipitation of mutant ARSAs 
BHK cells were transiently transfected with the mutagenesis vector using 
lipofectamine, as described7. After 48h, the cells were harvested and ARSA activity was 
measured in cellular extracts using the artificial substrate p-nitrocatecholsulphate as 
described8. Protein was determined with the Biorad DC protein assay kit according to 
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the protocol supplied by the manufacturer. Western blot analysis was performed with an 
ARSA antiserum raised against recombinant ARSA in rabbits. 
For the generation of stably transfected Ltkf cell lines, the mutated ARSA cDNA 
was subcloned into the expression vector pBEH6. A neomycine cassette, containing a 
neomycin resistance gene with an SV40 promoter and a polyadenylation signal, was 
inserted at the unique Aat II restriction site of the pBEH plasmid. The Ltk" cells were 
transfected using lipofectamine7, and selected for two weeks with lmg/ml G418. 
Metabolic labelling and immunoprecipitation of ARSA were done, as described 
previously in detail . 
The generation and characterisation of monoclonal anti-ARSA antibodies has 
been described in reference 10. 
Results 
Consequences of the F219V substitution 
The entire ARSA gene of the patient was amplified and sequenced completely. 
Only one sequence alteration was found in exon 3. A T > G transition at cDNA position 
655 changes codon 219 from TTC coding for phenyalanine to GTC coding for valine. 
The patient is homozygous for this allele and no other mutation was found in the ARSA 
gene. 
To prove that this missense mutation affects ARSA activity, expression vectors 
coding for the wild type, a P425T and a F219V substituted ARSA were transiently 
transfected into BHK cells. The P425T substitution has recently been found in a juvenile 
patient with MLD and has been shown to be associated with residual enzyme 
activity11'12. Forty-eight hours after transfection, ARSA activity was measured in the cell 
104 
lysates. Almost no activity was expressed from the plasmid containing the F219V 
substituted cDNA, whereas low levels of residual activity were found in lysates of cells 
expressing the P425T substituted enzyme (see Figure 1, top). Western blot analysis 
revealed the presence of ARSA cross reacting material in all transfected cells, which 
allows the conclusion that the F219V mutation severely reduces the specific enzymatic 
activity of ARSA (Figure 1, bottom, Table 1). 
Table 1 - ARSA relative specific activity 
WT P425T F219V BHK 
ARSAactivity-ARSAendogenous activity (uU) 301,5 39 4,5 0 
Western-blot arbitrary units 2427 2654 3707 0 
Relative specific activity 100% 12% 1% -
To estimate the relative specific activities of the mutant enzymes, transiently transfected BHK 
cells were analysed for ARSA activity and ARSA cross-reacting material, determined by 
Western blot analysis. Western blot signals were quantified by laser scan densitometry of the 
X-ray films and are presented in arbitrary units. Relative specific activity was calculated as the 
quotient between ARSA activity and the Western blot signal. Results of P425T were already 
published in ref. 12. This mutation was used here as a control to allow direct comparison to the 
F219V mutation. 
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Figure 1 - ARSA activity in transiently transfected BHK cells. Wild-type (Wt), F219V and 
P425T substituted ARSA cDNAs were transiently expressed in BHK cells. Forty-eight hours 
after transfection ARSA activity was measured in the cell homogenates. ARSA activity was 
calculated as the average of five independent transfection experiments and is expressed as mU 
ARSA/ mg total protein. Bars show the standard deviation. To determine endogenous 
background sulfatase activity of BHK cells, the same vector, but with an insert encoding a non-
related protein, was also transfected and ARSA activity measured. Results for the P425T 
mutation were published earlier12, they were used here for direct comparison to the F219V 
mutation. The bottom of the figure shows the result of a Western blot analysis confirming the 
presence of ARSA cross-reacting material. 
To investigate whether the F219V substitution also affects the stability of 
ARSA, pulse chase experiments with stably transfected cells were performed (see 
Figure 2). Whereas wild type ARSA was stable during the chase period of 72h, the 
106 
majority of the F219V substituted ARSA was degraded already after 6 h. Thus, this 
enzyme is highly unstable. 
Figure 2 - Stability of F219V-ARSA. Stably transfected Ltk" cells expressing wild type or 
mutated ARSA were metabolically labelled for 3h with [35S]-methionine and chased for the 
times indicated in hours. ARSA was immunoprecipitated from the cell lysates, subjected to 
SDS-PAGE and visualized by a phosphoimager. 
To get a measure of the structural integrity of the F219V substituted enzyme, we 
immunoprecipitated wild type, F219V and P425T substituted ARSA from transiently 
transfected, metabolically labelled BHK cells with several monoclonal antibodies. These 
monoclonal antibodies have been shown to precipitate only the native non denatured 
enzyme10. Whereas the wild type ARSA and the P425T substituted enzyme can be 
precipitated with all monoclonal antibodies used, the F219V substituted ARSA could 
not be precipitated by any of these antibodies (see Figure 3). 
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Figure 3 - Reactivity of ARSA with monoclonal antibodies. Wild type, F219V and P425T 
substituted ARSA cDNAs were transiently transfected in BHK cells. Forty-eight hours after 
transfection, cells were labelled for 3h with [35S]-methionine. Cells were harvested and the cell 
homogenates were divided into four aliquots. From these aliquots ARSA was 
immunoprecipitated either by a polyclonal antiserum (pAS) or by the three structure sensitive 
monoclonal antibodies (A2, B2 and C), which recognize three different epitopes10. 
Degradation of mutant ARSA may occur in the ER and/or in the lysosomes. To 
investigate whether the F219V-ARSA can leave the ER, pulse-chase experiments were 
performed in the presence of NH4CI. NH4CI interferes with the intracellular sorting of 
newly synthesised lysosomal enzymes in a post-Golgi compartment, targeting them 
improperly to the secretory pathway. If upon addition of NH4CI, mutant proteins can be 
detected in the media of cultured cells, this indicates that these enzymes must have 
— I "\ 
passed the Golgi apparatus and thus, are able to leave the ER . Cells were pulse 
labelled with [35S]-methionine and chased in the absence or presence of NH4CI. ARSA 
was immunoprecipitated from cells and media (Figure 4). Without NH4CI only little 
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cross-reacting material is found in the medium for cells expressing the wild type or the 
F219V-ARSA. Upon addition of NH4CI about 50% of the wild type ARSA is found in 
the medium. In the presence of NH4CI about 20% of the mutant F219V enzyme is 
secreted indicating that at least some of the enzyme can pass through the secretory 
pathway. 
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Figure 4- Sorting of the mutant ARSA polypeptides. Ltk" cells stably expressing the wild 
type or the F219V-ARSA were pulse-labelled for 2h with [35S]-methionine and chased for 12h 
in the presence or in the absence of lOmM NH4CI. After immunoprecipitation, from the 
medium or from the cells, ARSA was subjected to SDS-PAGE and radioactive polypeptides 
were visualized and quantified by a phosphoimager. The presented results are the average of 
two independent experiments. The amount of ARSA cross reacting material which was found 
in the cells plus media after the 2h pulse period were taken as 100%. 
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Discussion 
Metachromatic Leukodystrophy in adults usually starts between 16 and 30 years, 
but onset has been described up to an age of 60 years14. Initially, behavioural 
abnormalities and emotional lability, together with psychiatric symptoms such as 
delusions or hallucinations, are common. After months to years, spastic paresis of the 
extremities, exaggerated tendon reflexes and pyramidal signs may occur. Atactic 
symptoms, extrapyramidal signs, progressive dementia and clinical signs of peripheral 
neuropathy such as flaccid paresis usually occur1. Basically, two groups of adult patients 
can be distinguished: patients in whom initially psychiatric symptoms and impairment 
of intellectual functions dominate over neurologic symptoms and, in contrast, patients 
who present early with neurologic deficits. Patients with the former phenotype 
frequently are carriers of the I179S allele, suggesting a genotype-phenotype correlation 
in adult patients with respect to the initial symptoms that they develop15' 16' 17. Adult 
patients also show variability with respect to the extent of affection of the peripheral and 
central nervous system. Patients have been described, who presented with isolated 
peripheral neuropathy and lacked central nervous system dysfunction ' ' ' . In 
contrast, other patients in whom psychiatric and intellectual deficits dominate frequently 
miss clinical signs of peripheral neuropathy22'23. Nevertheless, only few cases have been 
reported of patients with MLD and normal electrophysiological and histological 
results24' 25. The patient described here presented exclusively severe cognitive and 
intellectual impairment, 18 months after the onset of the disease, at the age of 37. She 
showed no signs of peripheral nervous system involvement. The sural nerve biopsies of 
the patient revealed no abnormalities and electrophysiological studies were within 
normal ranges on both upper and lower extremities. In addition, she was not atactic, 
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which is in accordance with the lack of lesions in the white matter of the cerebellum. 
Different kinetics of lysosomal storage of sulfatides in oligodendrocytes and Schwann 
cells, reduced segmental demyelination in the peripheral nerve and better tolerance of 
peripheral nerve tissues for sulfatide accumulation during adulthood or other genetic or 
epigenetic factors may be the reason for preserved function and normal morphology in 
rare instances. 
This patient is homozygous for a new mutation causing the substitution of 
phenylalanine 219 by valine. The clinical heterogeneity of MLD can partially be 
ascribed to the amount of residual enzyme activity that is associated with the genotype 
of the patient2'3. In most cases, adult patients are homozygous for alleles displaying 
residual enzyme activity. Here we have compared the activity that can be expressed 
from a cDNA, which is F219V substituted, and another cDNA that is P425T substituted. 
The latter mutation was found in a patient with the juvenile form of the disease and has 
been shown to be associated with residual enzyme activity ' . Surprisingly, the F219V 
substitution causes reduction of enzyme activity below the levels of the P425T mutation 
and therefore to an extent unexpected for an adult MLD patient. A reduced specific 
activity and reduced stability of the F219V substituted enzyme account for this 
reduction. The influence of NH4C1 on the sorting of the mutant enzyme reveals that, at 
least a fraction of the mutant enzyme is able to leave the ER and pass the Golgi 
apparatus. Upon addition of NH4CI to cells expressing the wild type enzyme, about 50% 
of ARSA cross-reacting material is found in the medium, whereas 50% remains inside 
the cell. In total, there is no loss of wild type ARSA polypeptides during the chase 
period. In contrast, after NH4C1 addition to cells expressing the F219V substituted 
enzyme, only about 40% of ARSA can be recovered (20% in the secretions, 20% 
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remaining intracellularly, see Figure 4). If the degradation of this mutant enzyme was 
exclusively lysosomal, one would have expected amounts in the medium that were 
comparable to the wild type enzyme. The low amount of enzyme found in the medium 
may indicate that the enzyme is partially retained and degraded in the ER. 
The reasons for the discrepancy between the low enzyme activity and the mild 
phenorype of the patient remain unclear. Similar phenomena have been described in 
patients with early onset displaying exceptionally high residual enzyme activities26. 
Since the assays performed in vitro usually determine the enzyme activity with an 
artificial water-soluble substrate, it is likely that in some cases they do not reflect the in 
vivo situation in which an insoluble lipid substrate is degraded. On the other hand, it is 
known that genetic factors not linked to the ARSA locus can influence the phenotype of 
patients27 and this may also be the case in the patient described here. Except for the low 
activity, other parameters also suggest that the F219V substitution affects the enzyme 
more severely than other adult type mutations. Thus, for the most frequent adult type 
P426L mutation it has been shown that the enzyme leaves the ER, is properly sorted in 
the Golgi apparatus and degraded in the lysosome . The reason for the instability is 
probably the lack of octamerization, which usually occurs in the low pH environment of 
the lysosome29. The F219V enzyme, however, seems to be at least partially retained in 
the ER. We have also used various monoclonal antibodies, which epitopes depend on 
the correct three-dimensional folding of the enzyme. Whereas the wild type enzyme and 
the P425T substituted enzyme retain the epitopes, the F219V enzyme is not recognized 
by any of these antibodies. This indicates that this mutation causes a severe structural 
alteration of the enzyme. This result is in accordance with the low specific activity of 
the enzyme. 
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In summary, we describe an adult onset case of MLD, caused by a newly 
identified mutation in the arylsulfatase A gene, F291V. This patient has no clinical, 
electrophysiological or morphological signs of peripheral nerve affection and is 
homozygous for an allele that expresses only low amounts of residual enzyme activity. 
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Abstract 
Arylsulfatase A (ARSA) is a lysosomal enzyme implicated in most cases of metachromatic leukodystrophy (MLD). The qua­
ternary structure of ARSA is pH­dependent: at neutral pH, ARSA is a homodimeric protein; at lysosomal (acidic) pH, ARSA is 
homo­octameric. This dimer­octamer transition seems to be of major importance for the stability of the enzyme in the lysosomal 
milieu. Sedimentation analysis was used to study the oligomerization capacity of C300F and P425T­substituted ARSA, two MLD­
associated forms of the enzyme displaying reduced lysosomal half­lives. P425T­ARSA displays a modest reduction in its octa­
merization capacity. In contrast, the C300F mutation strongly interferes with the octamerization process of ARSA but not with its 
dimerization capacity. Interestingly, a major fraction of dimeric ARSA­C300F is composed of covalently linked ARSA molecules, 
through a thiol­cleavable bond that probably involves Cys414 residues from each monomer. Our data support the notion that the 
reduced lysosomal half­life of some mutated forms of ARSA is related to deficient octamerization. 
© 2003 Elsevier Science (USA). All rights reserved. 
Keywords: Arylsulfatase A; Metachromatic leukodystrophy; Protein stability; Lysosome 
Arylsulfatase A (ARSA) is a lysosomal enzyme in­
volved in the catabolism of various sulfate­containing 
substrates. The major physiologic substrate of ARSA is 
3­0­sulfogalactosyl ceramide (sulfatide) which accounts 
for 3.5­4% of the total lipids of myelin. 
ARSA has been crystallized and its three­dimensional 
structure has been solved. The core of the enzyme con­
sists of two p­pleated sheets, linked together by several 
hydrogen bonds and one disulfide bridge (Cys300­
Cys414). The large central (3­pleated sheet is decorated 
on both sides by several helices such that the enzyme has 
high structural resemblance to bacterial alkaline phos­
phatase [1]. 
The quaternary structure of ARSA is highly pH de­
pendent. The enzyme oscillates between two states: di­
meric and octameric. At neutral pH the dimeric form 
predominates; at the lysosomal acidic pH the enzyme 
' Corresponding author. Fax: +351­22­609­2404. 
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exists mainly as a homo­octamer, composed of four 
dimers arranged in a ring­like structure. This pH­
dependent dimer­octamer equilibrium is regulated by 
deprotonation­protonation of Glu424, whereas the 
non­covalent dimerization involves other regions of the 
enzyme and is not pH dependent [1]. 
Mutations in the ARSA gene are, by far, the most 
frequent cause of metachromatic leukodystrophy 
(MLD), a lysosomal storage disorder with autosomal 
recessive inheritance. The intralysosomal accumulation 
of sulfatide occurs mainly in oligodendrocytes, Schwann 
cells and neurons, and to a lesser extent in visceral 
organs like kidney, gallbladder, and liver [2]. 
Presently, more than 90 different disease­causing 
mutations in the ARSA gene are known (Human­
GeneMutationDatabase). For many of these muta­
tions a clear relationship between the observed genetic 
alteration and the enzymatic deficiency can be easily 
established. This is the case for some non­sense mu­
tations or for site­splicing mutations that strongly 
0006­291X/03/S ­ see front matter © 2003 Elsevier Science (USA). All rights reserved. 
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interfere with the production of a normal mRNA 
[3-5]. However, in the case of missense mutations this 
task requires extensive biochemical experiments, de-
spite the fact that the three-dimensional structure of 
ARSA is already known [1]. A recent report on the 
properties of ARSA-P426L, a mutated ARSA form 
displaying a normal enzymatic specific activity, illus-
trates this point [6]. X-ray analysis of crystallized 
ARSA-P426L failed to reveal any major structural 
alteration. However, ARSA-P426L is a very unstable 
enzyme in lysosomes. A complete biochemical char-
acterization of this protein provided the answer to this 
problem: the P426L mutation negatively interferes 
with the octamerization of ARSA, a process that must 
occur in order to yield a protease-resistant enzyme 
capable of surviving in the hostile lysosomal com-
partment. Thus, even a subtle conformational alter-
ation in the structure of ARSA may produce a 
dramatic effect on its in vivo stability. 
In a previous work we described two MLD-asso-
ciated mutations in the ARSA gene [7]. The first 
mutation, ARSA-C300F, was found in a homozygotic 
state in a child displaying a severe phenotype of 
MLD. The second mutation, ARSA-P425T, was found 
in a juvenile patient, in heterozygosity with one of the 
most frequent mutations in MLD, the P426L mutation 
[4]. More recently, we demonstrated that ARSA-
C300F displays an almost null specific enzymatic ac-
tivity whereas ARSA-P425T was found to have 12% 
of the activity of the normal enzyme. Data suggesting 
that both mutated forms are correctly targeted to 
the lysosomal compartment were also provided. 
However, pulse-chase analysis revealed that both mu-
tated enzymes are rapidly degraded in the lysosome 
[8]. 
As an attempt to understand the reduced half-lives of 
these two ARSA mutant forms, we have analyzed their 
homopolymerization capacity. Our results indicate that 
ARSA-P425T displays a reduction in its octamerization 
capacity. The octamerization capacity of ARSA-C300F 
is highly reduced. Interestingly, ARSA-C300F is able to 
form dimers implying that formation of the Cys300-
Cys414 disulfide bond is not a prerequisite for the di-
merization process of the enzyme. Furthermore, a major 
fraction of dimeric ARSA-C300F is composed of cova-
lently linked ARSA molecules, through a thiol-cleavable 
covalent bond that probably involves opposing Cys414 
residues from each monomer. It is hypothesized that the 
structural alterations occurring at the monomer-mono-
mer interface in the ARSA-C300F enzyme change the 
association angle of the two monomers impairing the 
octamerization process. 
These data lend support to the notion that a defi-
ciency in the octamerization process of ARSA may be 
the reason behind the reduced lysosomal half-lives of 
some mutated forms of this enzyme. 
Materials and methods 
Materials. Cell culture media, antibiotics, and fetal calf serum were 
from Invitrogen Life Technologies. Mammalian protease inhibitor 
cocktail was from Sigma. Centricon-10 concentrators were from Am-
icon. The High Molecular Weigh Calibration Kit was from Amer-
sham-Pharmacia Biotech. Other reagents were from Sigma. 
Arylsulfatase A activity determination. ARSA activity determina-
tion was done using the artificial ARSA substrate /Miitrocatechol 
sulfate [9]. 
Sample preparation. Stably transfected Ltk~ cell lines expressing 
C300F-ARSA, P425T-ARSA, and WT-ARSA have been previously 
generated [8]. These cells were maintained in Dulbecco's modified 
Eagle's medium (DMEM), 5% fetal calf serum. Sixteen confluent 
75 cm2 flasks of Ltk" cells expressing C300F-ARSA, P425T-ARSA, or 
WT-ARSA were harvested. The cells were sonicated in 0.02% (w/v) 
Triton X-100 with 520 uM AEBSF, 0.4 uM aprotinin, 10.5 uM leu-
peptin, 18 uM bestatin, 7.5 uM pepstatin A, 7uM E-64, 50 uM io-
doacetamide, 10 uM PMSF, and 1 mM EDTA. The suspensions were 
first clarified by a 20 min centrifugation at 15,000g and the superna-
tants were then subjected to a 20 min ultracentrifugation at 145,000,1» 
using a T-1270 rotor (Sorvall). The cleared supernatants were con-
centrated fourfold using Centricon-10 concentrators from Amicon. 
Sedimentation analysis. Cell extracts containing 240 mU WT-
ARSA activity or, in the case of the mutants, an equivalent amount of 
ARSA protein as quantified by Western blotting analysis (see below), 
were diluted with appropriated buffer (lOmM Tris-HCl, 150 mM 
NaCl (pH 7.0) or 100mM NaAc/HAc, and 150mM NaCl (pH 4.8 or 
pH 5.2)) to a final volume of 500 ul. The samples were then applied 
onto the top of discontinuous sucrose gradients (1.8ml of 7.5%, 1.8 ml 
of 10%, 1.7ml of 15%, 1.6ml of21%, 1.5 ml of 25%, and 1.4ml of 30% 
(w/v) sucrose in the buffer used to prepare the corresponding sample). 
After centrifugation at 165,000g for 16h,at4°C,inaTST41.14swing-
out rotor (Sorvall), 12 fractions of 0.86ml were collected from the 
bottom of the tube. 
The High Molecular Weigh Calibration Kit from Amersham-
Pharmacia Biotech was used to calibrate the gradients. 
SDS-PAGE and Western blot. Proteins present in each gradient 
fraction were precipitated with 10% (w/v) trichloroacetic acid. After 
30 min on ice, the precipitated protein was pelleted (15 min at 15,000g), 
washed with acetone, solubilized in Laenrmli sample buffer [10], and 
analyzed by SDS-PAGE and Western blotting using an ARSA anti-
serum, raised against recombinant ARSA in rabbits. SDS-PAGE was 
performed in 1.0 mm thick, 10% polyacrylamide gels using the Laemmli 
discontinuous buffer system [10]. 
Results and discussion 
Sedimentation analysis was used to compare the 
oligomerization capacity of C300F and P425T-ARSA 
mutants with WT-ARSA. As shown in Fig. 1, at pH 4.8 
about 75% of WT-ARSA is found in fractions 4-6 
corresponding to an apparent molecular mass of c.a. 
500 kDa. This value is in good agreement with a mo-
lecular mass of about 496 kDa, the theoretical value 
expected for the ARSA octamer. About 20% of ARSA 
is found in fractions 8-10 (estimated molecular mass of 
120 kDa c.a.), indicating that dimeric WT-ARSA (cal-
culated molecular mass of 124 kDa) is also present un-
der these experimental conditions. At pH 5.2, the 
amount of wild type ARSA in the octameric form de-
creases to about 60% of total (Fig. 1A, fractions 4-6) 
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Fig. 1. Oligomerization of WT-ARSA, C300F-ARSA, and P425T-ARSA at different pH. WT, C300F, and P425T-ARSA were subjected to sucrose 
gradient centrifugation at pH 4.8, pH 5.2, and pH 7.0. After fractionation of the gradients (1-12 fractions from bottom to top) proteins were 
analyzed by SDS-PAGE and Western blot. Native molecular mass markers used to calibrate the gradient (pH 7.0): thyroglobiilin (Tyr, fraction 3, 
669 kDa), catalase (Cat, fraction 6,232 kDa), lactate dehydrogenase (LDH, fraction 8,140 kDa), and bovine serum albumin (AL, fractions 9 and 10, 
67 kDa). At pH 4.8, the thyroglobiilin and the lactate dehydrogenase precipitated, but catalase and bovine serum albumin maintained their local-
ization. The results presented in the graphics result from the quantification of Western blot signals by laser scan densitometry of X-ray films. At pH 
4.8, we considered dimers at fractions 8-10 and octamers at fractions 4-6. At pH 5.2, we considered dimers at fractions 7-9 and octamers at fractions 
4 -6 , with the exception of P425T-ARSA octamers that we considered at fractions 3-5. 
while the amount in the dimeric form increases to about 
40% (Fig. 1A, fractions 7-9). At pH 7.0, the vast ma-
jority of the wild type enzyme is detected as a dimer 
(fractions 7-9, Fig. 1) as expected [1]. 
When the sedimentation properties of ARSA-P425T 
were analyzed, a different behavior was observed. At 
p H 4.8, the amount of ARSA-P425T in the octameric 
state is clearly lower than the one observed for the 
normal enzyme (see Fig. IB). At pH 5.2, this difference 
is still detected, although not so markedly, suggesting 
tha t the P425T substitution not only shifts the pH at 
which half of ARSA exists as a octamer towards lower 
values (c.a. pH 4.8), but also the profile of the dimer-
octamer equilibrium as a function of pH. Although no 
attempts were made to quantify these two variables, the 
data obtained for ARSA-P425T are very similar to the 
results described recently for the P426L mutation [6]. 
N o effects on the dimerization capacity of ARSA-
P425T were noted in these experiments, (see Fig. 1, 
panel "pH 7.0"). 
In contrast with the results described above, the C300F 
mutation was found to have a dramatic effect on the oc-
tamerization process of the enzyme. Indeed, as shown in 
Fig. 1, only a small fraction of ARSA-C300F behaves as 
an octameric protein at pH 4.8. At pH 5.2, octameric 
ARSA-C300F is no longer detected (Figs. 1A and B). 
These data indicate that the C300F mutation induces 
conformational alterations in ARSA such that the octa-
merization process of the enzyme is highly affected. 
As mentioned above, Cys300 forms an intramolecular 
disulfide bridge with Cys414. These two cysteines localize 
at the monomer-monomer interface (and not at the di-
mer-dimer interface). Thus, the observation that C300F 
mutation interferes with the octamerization process of 
ARSA would be easy to understand if dimerization of 
ARSA-C300F was impaired. Strikingly, this is clearly 
not the case. As shown in Fig. 1, the majority of ARSA-
C300F behaves as a dimeric protein upon sedimentation 
analysis at all the pHs tested. How can this result be 
explained? Perhaps the easiest explanation would be to 
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assume that the C300F substitution results in a distortion 
of the monomer-monomer interface changing the asso-
ciation angle of the two molecules. Such dimers could 
still interact with other dimers but a stable ring of four 
dimers would be difficult to obtain. Although this hy-
pothesis remains speculative, data showing that indeed 
some structural alterations at the monomer-monomer 
interface are introduced by the C300F mutation were 
obtained when the behavior of ARSA was analyzed by 
non-reducing SDS-PAGE. As shown in Fig. 2, when 
WT-ARSA is subjected to SDS-PAGE only a single 
band (apparent molecular mass of 62 kDa) correspond-
ing to the monomeric protein is observed, as expected. In 
contrast, ARSA-C300F displays a dual behavior: a 
fraction of the enzyme co-migrates with the WT-ARSA; 
the other fraction of ARSA-C300F migrates as a 
124 kDa protein. Under reducing conditions this 
124 kDa protein band disappears with the concomitant 
increase of the 62 kDa protein band (monomeric ARSA-
C300F; see lane 4). These data, together with the ob-
servation that only one protein (corresponding to 
ARSA) is immunoprecipitated from 35S-labeled Ltk~ 
cells expressing ARSA-C300F by an anti-ARSA anti-
body [8], indicate that the 124 kDa species represents a 
dimer of ARSA in which the two monomers are linked 
together by at least one disulfide bridge. 
The three-dimensional structure of WT-ARSA re-
veals that from the 14 cysteines present in the molecule 
only Cys38 and Cys294 are in a reduced state. In ARSA-
C300F, an additional reduced cysteine would be ex-
pected: Cys414. Although all these three cysteines are 
located at the monomer-monomer interface, it is plau-
sible to assume that the structure of Cys414 will be the 
most affected by the C300F substitution. The presence 
—*" *—116 
+V66 
1 2 3 4 
Fig. 2. Non-reducing SDS-PAGE analysis of the C300F-ARSA mu-
tant. Proteins in homogenates of Ltk" cells, stably expressing WT 
(lanes 1 and 3; 80 ug protein/lane) and C300F-ARSA (lanes 2 and 4; 
200 ug protein/lane), were resolved by SDS-PAGE, under reducing or 
non-reducing conditions, and analyzed by Western blot. Lanes 1 and 
2—the homogenates were incubated with 20 mM IAA, for 10 min, at 
room temperature and with Laemmli sample buffer, without DTT, for 
5 min at 90 °C, before being applied on the SDS-PAGE gel. Lanes 3 
and 4—the homogenates were incubated with 20 mM IAA for 10 min, 
at room temperature, and with lOOmM DTT and Laemmli sample 
buffer for 5 min at 90 °C, before being applied on the SDS-PAGE gel. 
The numbers in the right indicate the molecular masses of the applied 
standards in kDa. 
of the hydrophobic and bulky side chain of a phenyl-
alanine at this position could not only induce a re-
orientation of the sulfide group of Cys414 towards the 
exterior of the monomer but also bring in close prox-
imity, at the monomer-monomer interface, the sulfide 
groups of Cys414 from each monomer. 
The aim of the work presented here was to address 
the relationship between the reduced in vivo half-life of 
some MLD-associated ARSA mutant forms and their 
oligomerization capacities. As suggested recently [6], 
mutations in the ARSA protein impairing its pH-
dependent octamerization result in unstable enzymes 
rapidly degraded by lysosomal cathepsins. We selected 
for this study two mutated forms of the enzyme: ARSA-
P425T and ARSA-C300F, both displaying a reduced 
half-life [8]. The first mutation involves an amino acid 
residue adjacent to Glu424, the proposed molecular 
switch controlling the pH-dependent dimer-octamer 
transition of ARSA [1]. Thus, considering the short half-
life of ARSA-P425T, a deficient octamerization capacity 
for this mutated ARSA form would be expected, as 
described recently for ARSA-P426L [6]. Indeed, such 
phenomenon was observed—although ARSA-P425T is 
able to octamerize, the efficiency of this process is clearly 
lower than the one displayed by the normal enzyme. 
The second mutation characterized in this work in-
volves the substitution of cysteine 300 by a phenylala-
nine. In the normal enzyme, Cys300 lies at the 
monomer-monomer interface establishing an intramo-
lecular disulfide bridge with Cys414. Thus, a priori, 
some effect (if any) on the dimerization process of this 
mutated ARSA enzyme would be expected. Strikingly, 
the octamerization (and not the dimerization) process of 
ARSA-C300F is highly impaired, a property that 
probably reflects the existence of an altered association 
angle of the two ARSA monomers. As described for the 
ARSA-P426L mutated form [6], it is possible that this 
incapacity of ARSA-C300F in forming an octameric 
structure results in an increased accessibility to the 
lysosomal proteases. 
In summary, the data presented here suggest that an 
impairment in the octamerization process of ARSA may 
be the reason behind the lysosomal instability of some 
mutated ARSA forms. 
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CHAPTER 3. GENERAL CONCLUSIONS 
Chapter 3. General Conclusions 
GENERAL CONCLUSIONS 
A. Genetic epidemiology of ARSA deficiencies 
1. Metachromatic Leukodystrophy 
MLD is a severe lysosomal storage disorder due to deficient activity of the 
enzyme Arylsulfatase A. The human ARSA gene has been cloned and characterised 
already in 1990 (Kreysing et al, 1990), and more than ninety MLD-causing mutations 
have been so far described in different populations (von Figura et al, 2001 and 
www.hgmd.org). Nevertheless, regarding the genetic epidemiology of this pathology in 
Portugal, nothing was known before this work. The results presented here, concerning 
the molecular characterization of the Portuguese MLD patients, are thus an important 
contribution to the understanding of the genetic epidemiology of this disease. 
Comparing our results with those obtained for other European populations 
(Chapter 1 - Section 1A.2, Figure 1) we observed that the most prominent differences 
are the higher frequency of the ARSA null mutation IVS2+1G>A, which represents 
60% of the MLD alleles among unrelated Portuguese patients, and the lower frequency 
of mutation P426L, which represents only 3% of those alleles. Both these mutations 
have been reported to have a frequency of 25% each among European MLD patients 
(Polten et al, 1991). The highest frequency of IVS2+1G>A mutation reported in 
Europe was around 40% and was found in the British population (Barth et al, 1993a). 
Mutation P426L also was not found among the Spanish population (Gort et al, 1999). 
In spite of the high frequency of mutation IVS2+1G>A in Portugal, our results 
also illustrate the molecular heterogeneity that is reported to be associated with MLD: 
eight different mutations (c412insC, IVS2+1G>A, I179S, D255H, C300F, cl040delC, 
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P425T, P426L) were found among the sixteen families studied, three of them (C300F, 
cl040delC, P425T) were never reported in non-Portuguese patients. Portuguese thus 
seem to have a unique mutation profile regarding MLD, and this first molecular 
characterisation of Portuguese families will facilitate the posterior study of other MLD 
Portuguese patients. 
The study of the haplotypes associated with specific genetic alterations can be 
important for the characterisation of a mutational event, thus contributing to the 
understanding of the general aspects of the occurrence of genetic alterations, but can 
also provide some interesting clues regarding the movements of the populations. Based 
on the linkage disequilibria between mutation IVS2+1G>A and a single rare haplotype, 
this mutation was proposed to have an ancient single European origin (Zlotogora et al, 
1994a). Its high frequency in different regions of Portugal, together with its appearance 
in linkage disequilibria with the same single rare haplotype, seems to indicate that this is 
a very ancient mutation in our population. The Portuguese could even have contributed 
to its spread among other populations, at the time of the Crusades, as was speculated by 
Zlotogora etal, (1994a). 
Haplotyping has also been done for the other MLD mutant alleles and our results 
were in agreement with the fixed haplotypes previously proposed for mutations P426L, 
I179S and D255H (Coulter-Mackie et al, 1997b). In spite of the small number of 
unrelated cases reported, the possible existence of common ancestors is suggested. 
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2. Arylsulfatase A-pseudodeficiency 
Arylsulfatase A-pseudodeficiency is a relatively frequent but poorly understood 
condition, which is characterised by a reduction of ARSA normal activity, but is not 
associated with a MLD clinical phenotype (von Figura et al, 2001). The genetic 
polymorphisms in the basis of ARSA-PD were identified (Gieselmann et al, 1989) and 
their frequency determined in different populations (von Figura et al, 2001). The 
interference of this condition in the biochemical diagnosis of MLD is well known (von 
Figura et al, 2001), but once again nothing was known regarding its epidemiology in 
Portugal. 
Approximately eighteen percent of the Portuguese are carriers of one of the three 
alleles known to be associated with the ARSA-PD: 9,3% have the 2417G/ 3352G allele 
while 8,7% have the 2417G/ 3352A allele. The 2417A/ 3352G allele was found in only 
one individual. Taking the frequencies of the three alleles altogether, this is the highest 
value reported in a European population, which demonstrates the importance of this 
condition in Portugal. 
The haplotype analysis of ARSA-PD alleles in different populations has long 
raised several hypotheses regarding the order of appearance of the alterations that 
characterise the ARSA-PD alleles and its appearance as a single or a recurrent event 
(Zlotogora et al, 1994a, Ott et al, 1997). The determination of the haplotype associated 
with ARSA-PD and non-ARSA-PD alleles was also done in this work. 
Seventeen different haplotypes were identified in non-ARSA-PD alleles, 
whereas the ARSA-PD allele 2417G/ 3352G was found to be exclusively associated to 
one of the rare haplotypes: Bgl I (T) Bsr I (C) Bam HI (G) Nla III2 (G) Nla III1 (G) Aci I 
(G), which was found in 8,6% of the normal alleles and in none of the ARSA-PD alleles 
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2417G/ 3352A. In contrast, the ARSA-PD alleles 2417G/ 3352A and 2417A/ 3352G 
were found associated to different haplotypes. 
These results seem to confirm the association of the ARSA-PD allele 2417G/ 
3352G with a highly conserved haplotype (Zlotogora et al, 1994a) which together with 
its high frequency in Europeans and its absence in non-Europeans (Ott et al, 1997), 
strongly suggests a single ancient origin posterior to the divergence of European and 
Asian populations. 
On the other hand, the identification of the ARSA-PD alleles 2417G/ 3352A and 
2417A/ 3352G in different haplotypes does not allow us to exclude the possible 
existence of de novo mutations on different haplotype backgrounds nor the possible 
divergence of the polymorphic backgrounds of the mutated alleles. 
B. Structural/ functional relationships of ARSA 
ARSA has been extensively studied and its three-dimensional structure is 
already known (Lukatela et al, 1998). Nevertheless, a clear relationship between an 
observed genetic alteration in the ARSA gene and the consequent enzymatic deficiency 
is not always easy to establish, and in the case of missense mutations can require 
extensive biochemical experiments and reveal unsuspected results. 
Three novel missense mutations were biochemically characterised in this work: 
mutations C300F and P425T, found in two Portuguese families, and mutation F219V, 
found in one patient of Tamil origin. These mutations were found to be associated with 
different clinical forms of MLD: C300F mutation was found in homozygosity in one 
late infantile patient; mutation P425T was found in one juvenile patient; and mutation 
F219V was found in homozygosity in one adult patient. 
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Unexpectedly, the F219V mutation was found to cause a severe reduction of 
ARSA activity, below the levels that would be expected to an MLD adult patient with 
such a very late onset. This reduced activity was determined to be due to low stability of 
the mutant enzyme and to a reduced specific activity. Despite the fact that its sorting is 
affected by NH4C1, which indicates that at least part of it is able to escape from the ER, 
its indirect structural analysis based on its recognition by several monoclonal antibodies 
revealed that it might have a severe structural alteration. 
Regarding the mutations found in the Portuguese patients, no enzyme activity 
could be expressed from C300F allele, while about 10% residual enzyme activity could 
be expressed from P425T allele. Biosynthesis studies revealed that both mutant 
enzymes are unstable and their increased cellular secretion upon addition of NH4CI 
suggests that, at least part of these enzymes is able to reach the Golgi compartment. 
This is also supported by the presence of mannose 6-phosphate residues on the 
oligosaccharide side chains of the mutant enzymes. 
The relationship between the reduced in vivo half-live of both these mutants and 
their oligomerization capacities was also addressed and our data support the notion that 
the reduced lysosomal half-life of some mutated forms of ARSA might be related to 
deficient octamerization. 
Mutation P425T affects an amino acid residue adjacent to Glu424 that is 
proposed to be responsible for the pH-dependent dimer-octamer transition of ARSA 
(Lukatela et al, 1998). Therefore, the deficient octamerization capacity of this mutant 
could be expected, as described for other ARSA mutants with short half-live (von 
Bulowitfa/.,2002). 
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Mutation C300F affects an amino acid residue that lies at the ARSA monomer-
monomer interface establishing an intramolecular disulfide bridge with Cys414. Thus, 
some effect on the dimerization process of this mutated ARSA enzyme could be 
expected. 
Our results indicate that ARSA-P425T displays a reduction in its octamerization 
capacity, while the C300F mutation strongly interferes with the octamerization process 
of ARSA but not with its dimerization capacity. This implies that formation of the 
Cys300-Cys414 disulfide bond is not a prerequisite for the dimerization process of the 
enzyme. We could also observe that a major fraction of dimeric ARSA-C300F is 
composed of covalently linked ARSA molecules, through a thiol-cleavable bond that 
probably involves opposing Cys414 residues from each monomer. This observation 
allowed us to speculate that the structural alterations occurring at the monomer-
monomer interface in the ARSA-C300F enzyme change the association angle of the two 
monomers impairing the octamerization process. 
As described for the ARSA-P426L mutated form (von Biilow et al., 2002), it is 
thus possible that the incapacity of ARSA-C300F and ARSA-P425T in forming an 
octameric structure results in an increased accessibility to the lysosomal proteases, 
which could explain their low stability. 
C. Genotype-phenotype correlation in MLD 
The existence or not of a genotype-phenotype correlation in "monogenic" 
disorders can be important for the prediction of the age of onset and clinical progression 
of the disease in each individual, but is also important to the understanding of the 
general mechanisms of the pathology. In some cases, the non-existence of a genotype-
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phenotype correlation can provide important clues regarding the importance of other 
genetic or environmental factors. 
It is usually accepted that a general genotype-phenotype correlation exists in 
MLD and that the clinical heterogeneity observed in this pathology is due to different 
amounts of residual enzyme activity. In general, patients with two null mutations 
present the late infantile form, while the presence of at least one mutation leading to 
some residual activity mitigates the course of the disease leading to juvenile or adult 
forms (von Figura et al, 2001). Once again our results corroborate this general rule: the 
late infantile patients here analysed have two alleles codifying enzymes with null 
activity (IVS2+1G>A/ IVS2+1G>A, IVS2+1G>A/ c412insC, IVS2+1G>A/ D255H, 
cl040delC/ cl040delC, C300F/ C300F), while the late-onset patients Guvenile and 
adult forms) have one or two alleles codifying enzymes with some residual activity 
(IVS2+1G>A/ I179S, P425T/ P426L). 
In spite of this general correlation, the prediction of the onset and evolution of 
the disease based on the genotype is not straightforward and some clinical heterogeneity 
can be observed among individuals with the same genotype, even within the same 
family, and especially in the case of the adult patients. This may be related with their 
longer life expectancy, which allows the effect of other environmental or genetic factors 
to become more evident. 
In fact, some inter and intrafamilial heterogeneity, regarding the age of onset and 
clinical evolution, could be observed among the adult MLD patients discussed here, 
which have the same genotype (IVS2+1G>A/ I179S). Some biochemical heterogeneity 
could also be observed regarding the elevated sulfatide excretion in urine, which was 
present only in one of these families. In these specific cases, the presence of mutation 
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I179S, which originates a protein with some residual enzyme activity and that is known 
to be particularly susceptible to proteolytic degradation (Fluharty et al, 1991), can also 
contribute to this heterogeneity. The different amount of lysosomal proteases in each 
individual could explain this variability. Juvenile and adult patients have been reported 
with this mutation. Some of the adult patients are compound hétérozygotes with a null 
mutation (Fluharty et al, 1991; Berger et al, 1997). 
In spite of the observed variability, the recently suggested association of 
mutation I179S with early psychiatric symptoms and intellectual impairment (Baumann 
et al, 2002) could also be observed in our patients. 
Other examples also raise some doubts regarding the genotype-phenotype 
correlation in MLD. In our results this is illustrated by the identification of mutation 
F219V, which revealed to be associated with a severe reduction of ARSA activity, in a 
37 years old woman that presented exclusively severe cognitive and intellectual 
impairment. Furthermore, this F219V-ARSA seems to be partially retained in the ER 
and might have a severe structural alteration. 
On the other hand, at least one patient has been described presenting high 
residual enzyme activities but an early onset of the disease (Kreysing et al, 1993). Both 
these examples illustrate a lack of correlation between the biochemical and the clinical 
phenotype that remains unexplained, and they seem once again to indicate that in spite 
of the genotype-phenotype correlation usually accepted to exist in MLD, other factors, 
genetic or environmental, might affect the disease's onset and progression. 
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D. Implication of ARSA-PD in the pathogenesis of non-MLD related pathologies 
The high frequency of the ARSA-PD associated alleles among the general 
population (von Figura et al, 2001) and their almost constant combined frequency in 
different populations (Ott et al, 1997), might suggest an advantage for the carriers of 
ARSA-PD alleles. Nevertheless, to date there are no plausible hypotheses for this 
advantage. 
On the other hand, the possibility that ARSA-PD is implicated in the 
pathogenesis of other non-MLD associated pathologies could not also be excluded, in 
spite of the large number of studies that have been done on this subject (von Figura et 
al., 2001). 
One strong possibility that remains to be proved is the higher susceptibility of 
individuals with ARSA-PD to develop psychiatric alterations. The fact that some MLD 
adult patients present early clinical signs that lead to the misdiagnosis of schizophrenia 
make the schizophrenic patients an interesting candidate group to test ARSA-PD. 
The determination of the frequency of the ARSA-PD associated alleles among a 
group of Portuguese patients with schizophrenia revealed a statistically significant 
higher frequency of allele 2417G/ 3352A. If this result is confirmed in a larger sample, 
this can reveal to be an important contribution to the elucidation of the clinical 
implications of ARSA-PD, although the mechanism on the basis of this association will 
remain to be elucidated. 
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FUTURE PROSPECTS 
1. Importance of specific ARSA amino acid residues to the structure and function 
of the enzyme 
ARSA has been intensively studied, not only to try to understand the cellular 
pathogenic mechanisms of MLD, but also to try to understand the normal cellular 
mechanisms of processing, targeting and activation of lysosomal soluble hydrolases and 
sulfatases. Its three dimensional structure was solved (Lukatela et al, 1998) and 
putative amino acid residues important for its structure and function were identified 
(Lukatela et al, 1998; Waldow et al, 1999). Some of this knowledge resulted from the 
biochemical characterisation of mutations that were found in MLD patients (von Bùlow 
et al, 2002). 
In spite of all these studies, in most cases of novel missense mutations is still not 
possible to predict the effect of the mutation on the structure and function of the 
enzyme. Thus, it is still important to continue characterising the novel mutations, not 
only in a perspective of a better understanding of the normal cellular mechanisms 
responsible for the enzyme's acquisition of normal structure and function, but also to try 
to understand the abnormal cellular processes associated with each mutation, which can 
be important to design therapeutic strategies. 
2. Additional genetic or environmental factors affecting ARSA activity "in vivo" 
Cases have been reported that raise some doubts regarding the existence of a 
straightforward genotype-phenotype correlation in MLD, or that at least raise the 
hypothesis of the existence of other genetic or environmental factors that influence the 
activity of ARSA in vivo (Alves et al, 1986; Clark et al, 1989; Polten et al, 1991). 
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Our own results seem to corroborate this hypothesis. The detection and further 
investigation of such cases may contribute to the identification of these factors, which 
can be important not only for the understanding of the pathogenesis of MLD but also to 
predict the age of onset and clinical evolution of the disease in each case. This can be 
also important to delineate different therapeutic approaches. 
Two possible factors that could modulate the enzyme's activity in vivo are the 
efficiency of the ARSA activator protein Saposin B, which could be affected by some 
genetic polymorphisms, and the pattern of lysosomal proteases characteristic of each 
patient, whose efficiency could also be affected by genetic polymorphisms at the level 
of the different proteases. 
It is also known that some of the mutants are retained at the ER level, and even 
if they have some residual activity they are not able to get in the lysosome. The different 
efficiency of the cellular machinery at the quality control level in the ER could also 
contribute to some variability. 
These factors, whose understanding can also contribute to the development of 
therapeutic strategies, are especially important when the mutated enzymes have some 
residual enzyme activity, which is frequently the case of the late-onset patients. 
3. Implication of ARSA-PD in the pathogenesis of pathologies other than MLD 
An increased susceptibility of individuals with ARSA-PD to develop 
neuropsychiatrie symptoms as been long hypothesised, although never proved. Our 
results seem to indicate the association between ARSA-PD and schizophrenia. 
However, the base for this association was not elucidated. 
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The GABA receptors have been implicated in the pathogenesis of some of the 
psychiatric conditions speculated to be associated with ARSA-PD, including 
schizophrenia (Arnold et al, 1999; Kittler et al, 2002). Additionally, sulfatide was 
reported to be implicated in the binding of GABA to its receptors (Chweh et al, 1983), 
although the nature of this implication and its physiologic significance are unknown, 
and at least one subtype of GABA receptors is associated with lipid raft microdomains 
(Bêcher et al, 2001). Recent reports also established the importance of sulfatide in the 
appropriate localization and maintenance of ion channels clusters (Ishibashi et al, 
2002). 
It could thus be interesting to analyse the correct formation, localization, 
stability and activity of the different GABA receptor subtypes. The generation of a 
transgenic mouse with low ARSA activity could be important not only to do this kind of 
studies, but also to verify the development of neurologic symptoms. 
4. New therapeutic approaches 
Several reports have recently been made regarding a possible new therapeutic 
strategy that uses chemical chaperones to stabilize mutant enzymes with some residual 
activity, but that are missfolded and thus retained in the ER and degraded through the 
proteasome. The activity of beta-glucosidase, alpha-galactosidase A and beta-
galactosidase, three lysosomal enzymes whose absence causes Gaucher Disease, Fabry 
Disease and GM1-gangliosidosis, respectively, could be enhanced in patients' cultured 
cells using inhibitors of these enzymes in subinhibitory intracellular concentrations (Fan 
et al, 1999; Asano et al, 2000; Tominaga et al, 2001; Sawkar et al, 2002). 
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The biochemical characterization of several ARSA mutants revealed that some 
of them are completely or partially retained in the ER, and thus even if they have some 
residual enzyme activity they are not able to get in the lysosome (Harvey et al, 1993; 
Kappler et al, 1994; Hess et al, 1996a; Hermann et al, 2000). In the cases of ER 
retention of a mutant with some residual enzyme activity, this kind of therapeutic 
approach may prove important, especially because there are no other proved alternatives 
for therapy in MLD. However, until today there are no such chemical chaperones 
reported to act on ARSA stabilization. 
Several ARSA mutants, usually associated with late-onset MLD, revealed to 
have some enzyme activity and to be able to reach the lysosome, but are rapidly 
degraded by the lysosomal proteases (Polten et al, 1991). Some of these mutants can be 
stabilized by inhibition of lysosomal proteases (von Figura et al, 1983), and thus the 
development of therapeutic strategies to stabilize this kind of mutants that are able to 
reach the lysosome and that have residual enzyme activity, but that are extremely 
sensitive to lysosomal proteases and rapidly degraded, could also be interesting. 
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